Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Een studie ter evaluatie van de werkzaamheid en veiligheid van orale etrasimod bij de behandeling van volwassen deelnemers met matig tot ernstig actieve ziekte van Crohn (CULTIVATE)

5 juni 2026 bijgewerkt door: Pfizer

Een multicenter, gerandomiseerde, dubbelblinde studie met parallelle groepen om de werkzaamheid en veiligheid van orale etrasimod als inductie- en onderhoudstherapie voor matig tot ernstig actieve ziekte van Crohn te beoordelen

Dit is een fase 2/3-onderzoek dat bestaat uit 5 deelonderzoeken die zijn opgezet om de werkzaamheid, veiligheid en verdraagbaarheid van oraal etrasimod als therapie te evalueren bij volwassen deelnemers met matig tot ernstig actieve ziekte van Crohn (CD) die refractair of intolerant zijn voor ten minste 1 van de de huidige therapieën voor CD (dwz corticosteroïden, immunosuppressiva of biologische geneesmiddelen). De totale duur van dit onderzoek is maximaal 282 weken, inclusief de screeningperiode van 28 dagen, de behandelingsperiode van maximaal 274 weken (inductie, verlenging of onderhoud en langdurige verlengingsperioden) en de follow-upperiode van 4 weken. Periode voor veiligheidsbeoordeling.

Studie Overzicht

Gedetailleerde beschrijving

Dit onderzoek omvat 5 deelonderzoeken:

Substudie A - Fase 2: Een fase 2, gerandomiseerde, dubbelblinde, substudie om de veiligheid, verdraagbaarheid en werkzaamheid van orale etrasimod-therapie te beoordelen bij deelnemers met matige tot ernstige coeliakie die de selectie van een inductie- en onderhoudsdosis(s) ondersteunt. voor fase 3. Deelstudie A is momenteel gesloten voor inschrijving.

Substudie 1 - Fase 2: een gerandomiseerde, dubbelblinde, placebogecontroleerde inductiesubstudie in fase 2b om etrasimod te evalueren als inductietherapie en een inductie- en onderhoudsdosis(s) te selecteren voor verdere evaluatie in fase 3. Substudie 1 is momenteel inschrijvende deelnemers.

Substudie 2 - Inductie: een gerandomiseerde, dubbelblinde, placebogecontroleerde fase 3-substudie om etrasimod als inductietherapie te evalueren.

Substudie 3 - Onderhoud: een gerandomiseerde, dubbelblinde, placebogecontroleerde fase 3-substudie om etrasimod als onderhoudstherapie te evalueren. Deelnemers uit Deelstudie 1 en Deelstudie 2 worden ingeschreven in Deelstudie 3.

Subonderzoek 4 - Langdurige verlenging: een langdurig verlengingssubonderzoek voor deelnemers die ten minste 52 weken behandeling hebben voltooid. Het is de bedoeling dat deelnemers uit deelonderzoek 3 en deelonderzoek A worden ingeschreven in deelonderzoek 4.

Studietype

Ingrijpend

Inschrijving (Werkelijk)

379

Fase

  • Fase 2
  • Fase 3

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studie Locaties

    • Prov. de Buenos Aires
      • Ciudadela, Prov. de Buenos Aires, Argentinië, 1702
        • Instituto Medico Elsa Perez(I.M.E.P)
      • Ciudadela, Prov. de Buenos Aires, Argentinië, B1702GIK
        • Instituto Medico Elsa Perez (I.M.E.P.) (Local Lab)
      • Ciudadela, Prov. de Buenos Aires, Argentinië, B1702GIK
        • Instituto Medico Elsa Perez (I.M.E.P.) (Pharmacy)
      • Hurlingham, Prov. de Buenos Aires, Argentinië, B1686NCI
        • Estudio de La Vision (OCT, Ophthalmoscopy)
    • Santa Fe Province
      • Rosario, Santa Fe Province, Argentinië, S2000DEJ
        • Instituto Medico de la Fundacion Estudios Clinicos
      • Rosario, Santa Fe Province, Argentinië, S2000AUC
        • Gastroenterologia Rosario (Endoscopy)
      • Rosario, Santa Fe Province, Argentinië, S2000CTC
        • Microcirugia Ocular SA (OCT, Ophthalmoscopy)
      • Rosario, Santa Fe Province, Argentinië, S2000KZD
        • Consultorios extemos de Sanatorio Parque (PFT with DLCO, Pulmonar Functional Test with DLCO)
    • Tucumán Province
      • San Miguel de Tucumán, Tucumán Province, Argentinië, T4000AXL
        • Centro de Investigaciones Médicas Tucuman
    • New South Wales
      • Macquarie University, New South Wales, Australië, 2109
        • Macquarie University Hospital
      • Macquarie University, New South Wales, Australië, 2109
        • Macquarie University Hospital Pharmacy
      • Macquarie University, New South Wales, Australië, 2109
        • Macquarie Respiratory Services
      • Macquarie University, New South Wales, Australië, 2109
        • Macquarie University Hospital Clinical Trials
      • Macquarie University, New South Wales, Australië, 2109
        • MQ Health Ophthalmology
    • Queensland
      • Brisbane, Queensland, Australië, 4029
        • Royal Brisbane & Women's Hospital
      • North Mackay, Queensland, Australië, 4740
        • Coral Sea Clinical Research Institute
    • Victoria
      • Bellfield, Victoria, Australië, 3081
        • MCES Practice Pty Ltd operating as Comprehensive Eye Surgeons
      • Epping, Victoria, Australië, 3076
        • The Northern Hospital
      • Heidelberg, Victoria, Australië, 3084
        • Austin Hospital
      • Melbourne, Victoria, Australië, 3011
        • Vision Eye Institute
      • Melbourne, Victoria, Australië, 3011
        • Footscray Hospital
      • Parkville, Victoria, Australië, 3050
        • The Royal Melbourne Hospital
      • Rosanna, Victoria, Australië, 3084
        • Heidelberg Eye Clinic
    • Western Australia
      • Murdoch, Western Australia, Australië, 6150
        • Fiona Stanley Hospital
      • Nedlands, Western Australia, Australië, 6009
        • Lions Eye Institute Limited
      • O'Connor, Western Australia, Australië, 6163
        • The trustee for The RTS Unit Trust trading as Respiratory Testing Services
      • Ghent, België, 9000
        • Universitair Ziekenhuis Gent
      • Ghent, België, 9000
        • AZ Maria-Middelares
      • Leuven, België, 3000
        • Universitaire Ziekenhuizen Leuven
      • Roeselare, België, 8800
        • Campus Brugsesteenweg
      • Roeselare, België, 8800
        • Campus Rumbeke
      • Torhout, België, 8820
        • Campus Rembert Torhout
      • Yvoir, België, 5530
        • Centre Hospitalier Universitaire UCL Namur - Site Godinne
      • Sofia, Bulgarije, 1527
        • UMHAT "Tsaritsa Yoanna-ISUL" EAD
      • Sofia, Bulgarije, 1431
        • "DCC Alexandrovska", EOOD
      • Sofia, Bulgarije, 1606
        • ,,University multiprofile hospital for active treatment and emergency medicine N.I. Pirogov" EAD
    • Quebec
      • Montreal, Quebec, Canada, H3G 1A4
        • McGill University Health Centre - Montreal General Hospital (Electrocardiogram Clinic)
      • Montreal, Quebec, Canada, H3G 1A4
        • McGill University Health Centre - Montreal General Hospital (Endoscopy Clinic)
      • Montreal, Quebec, Canada, H3G 1A4
        • McGill University Health Centre - Montreal General Hospital (Pharmacy)
      • Montreal, Quebec, Canada, H3G 1A4
        • McGill University Health Centre - Montreal General Hospital (Radiology)
      • Montreal, Quebec, Canada, H3G 1A4
        • McGill University Health Centre - Montreal General Hospital (Research Site)
      • Montreal, Quebec, Canada, H4A 3J1
        • Centre for Innovative Medicine - Research Institute of the McGill University Health Centre(Pulmonary
      • Montreal, Quebec, Canada, H4P 2S4
        • Eye Health MD (Ophthalmology)
    • RM
      • Santiago, RM, Chili, 8330034
        • Centro de Investigaciones Clinicas de la Universidad Catolica
    • Santiago Metropolitan
      • Santiago, Santiago Metropolitan, Chili, 7620157
        • Clinica Universidad de Los Andes
      • Santiago, Santiago Metropolitan, Chili, 8330336
        • CeCim Biocinetic
    • Quindío Department
      • Armenia, Quindío Department, Colombia, 630004
        • IPS Fundacion Cardiomet CEQUIN
    • Valle del Cauca Department
      • Cali, Valle del Cauca Department, Colombia, 760035
        • Centro de lnvestigaciones Clinicas S.A.S
      • Aalborg, Denemarken, 9000
        • Aalborg University Hospital, Department of Medical Gastroenterology, Medicinerhuset
      • Hvidovre, Denemarken, 2650
        • Hvidovre University Hospital
      • Augsburg, Duitsland, 86156
        • Universitaetsklinikum Augsburg
      • Brandenburg an der Havel, Duitsland, 14770
        • Staedtisches Klinikum Brandenburg
      • Frankfurt, Duitsland, 60431
        • Prof. Dr. med. Dr. med. Habil. Jens Buhren, FEBO
      • Frankfurt am Main, Duitsland, 60431
        • Agaplesion Markus Krankenhaus
      • Hamburg, Duitsland, 20251
        • HaFCED e.K. - Hamburgisches Forschungsinstitut für chronisch entzündliche Darmerkrankungen
      • Jena, Duitsland, 07747
        • Universitaetsklinikum Jena
      • Jena, Duitsland, 07747
        • OCT/Ophtalmoscopy address: Universitaetsklinikum Jena
      • Jena, Duitsland, 07747
        • PFT address: Universitaetsklinikum Jena
      • Kassel, Duitsland, 34121
        • PFT address: Praxis fur Pneumologie und Allergologie
      • Kassel, Duitsland, 34177
        • OCT/Ophtalmoscopy address: Augenarztpraxis Dr. Karola Hassan
      • Kiel, Duitsland, 24105
        • Nordblick Augenklinik
      • Kiel, Duitsland, 24105
        • Universitatsklinikum Schleswig-Holstein- Campus Kiel
      • Nürtingen, Duitsland, 72622
        • Dr. Irina Hasewinkel
      • Nürtingen, Duitsland, 72622
        • Medius Klinik Nuertingen
    • Hassen
      • Kassel, Hassen, Duitsland, 34117
        • Gastroenterologie Opernstraβe
      • Alexandria, Egypte, 21131
        • Alexandria Clinical Research Center , Faculty of Medicine , Alexandria University
      • Cairo, Egypte
        • National Hepatology and Tropical Medicine Research Institute
      • Cairo, Egypte, 11556
        • Ain Shams University Hospital
      • Cairo, Egypte
        • Air Force Specialized Hospital(AFSH)
      • Cairo, Egypte
        • Cairo University , Kasr Al Aini Hospital
      • Dakahlia, Egypte
        • Egyptian Liver Research Institute and Hospital ( ELRIAH)
      • Giza, Egypte
        • Theodor Bilharz Research Institute Research Ethics Committee
      • Menofeya, Egypte, 32511
        • National Liver Institute
      • Amiens, Frankrijk, 80054
        • CHU Amiens Picardie
      • Clermont-Ferrand, Frankrijk, 63000
        • Chu Gabriel Montpied
      • Clermont-Ferrand, Frankrijk, 63000
        • CHU De Clermont Ferrand - Hopital Estaing
      • Grenoble, Frankrijk, 38043
        • CHU Grenoble Alpes - Hopital Michallon
      • Grenoble, Frankrijk, 38043
        • Endoscopy: CHU Grenoble Alpes- Hopital Michallon
      • La Roche-sur-Yon, Frankrijk, 85925
        • CHD Vendee, Unite de Recherche Clinique
      • Lille, Frankrijk, 59037
        • CHU de Lille - Hôpital Claude Huriez
      • Lille, Frankrijk, 59037
        • Optical Coherence Tomography and Ophthalmology CHU de Lille Hopital Roger Salengro
      • Lille, Frankrijk, 59037
        • Pulmonary Function Test CHU Lille, Institut Coeur Poumon
      • Montpellier, Frankrijk, 34295
        • CHU Saint-Eloi
      • Montpellier, Frankrijk, 34295
        • Hopital Saint-Eloi - Pole Digestif - Hgea Recherche Clinique - Rdc
      • Nice, Frankrijk, 06202
        • CHU de Nice, Hopital 1'Archet 2
      • Reims, Frankrijk, 51100
        • Hopital Maison Blanche, CHU DE REIMS
      • Reims, Frankrijk, 51092
        • Hopital Robert Debre
      • Reims, Frankrijk, 51100
        • Hopital Robert Debre CHU DE REIMS
      • Saint-Etienne, Frankrijk, 42055
        • CHU Saint Etienne - Hôpital Nord
      • Saint-Priest-en-Jarez, Frankrijk, 42270
        • Optical Coherence Tomography and Ophthalmology
      • Saint-Priest-en-Jarez, Frankrijk, 42270
        • Pulmonary Function Test
      • Toulouse, Frankrijk, 31059
        • Hopital Rangueil
      • Toulouse, Frankrijk, 31300
        • Hopital Purpan PPR pole cephalique
      • Vandœuvre-lès-Nancy, Frankrijk, 54511
        • CHRU Nancy Brabois
      • Tbilisi, Georgië, 0160
        • LTD Aversi Clinic
      • Tbilisi, Georgië, 0159
        • LTD Institute of Clinical Cardiology
      • Tbilisi, Georgië, 0160
        • JSC Infectious Diseases, AIDS and Clinical Immunology Research Center
      • Tbilisi, Georgië, 0160
        • LTD Academician Nikoloz Kipshidze Central University Clinic
      • Tbilisi, Georgië, 0172
        • Malkhaz Katsiashvili Multiprofile Emergency Medicine Center, LTD
      • Tbilisi, Georgië, 0179
        • LTD Medical Center "CITO"
      • Alexandroupoli, Griekenland, 681 00
        • University General Hospital of Alexandroupoli
      • Athens, Griekenland, 10676
        • General Hospital of Athens "Evangelismos"
    • Crete
      • Heraklion, Crete, Griekenland, 71500
        • Univerisity General Hospital of Heraklion
      • Budapest, Hongarije, 1136
        • Pannonia Maganorvosi Centrum
      • Budapest, Hongarije, 1033
        • Clinexpert Egeszsegugyi Szolgaltato es Kereskedelmi Kft. (abbreviated name: Clinexpert Kft.)
      • Budapest, Hongarije, 1062
        • Ophthalmology procedures: Magyar Honvedseg Egeszsegugyi Kozpont
      • Budapest, Hongarije, 1062
        • Pulmonary procedures: Vasutegeszsegugyi Nonprofit Kozhasznu K ft.
      • Budapest, Hongarije, 1134
        • Ophthalmology, OCT: Medicover Zrt.
      • Budapest, Hongarije, 1139
        • Chest X-ray: XIII. keruleti Egeszsegugyi Szolgalat Kozhasznu Nonprofit Kft.
      • Békéscsaba, Hongarije, 5600
        • Bekes Megyei Kozponti Korhaz Dr. Rethy Pal Tagkorhaz, 4. Belgyogyaszat es 2. Gasztroenterologia
    • Heves County
      • Gyöngyös, Heves County, Hongarije, 3200
        • Bugat Pal Korhaz, Gasztroenterologia
    • Komárom-Esztergom
      • Tatabánya, Komárom-Esztergom, Hongarije, 2800
        • Szent Borbala Korhaz
      • Tatabánya, Komárom-Esztergom, Hongarije, 2800
        • DLCO and ophthalmology tests: Szent Borbala Korhaz
      • Kochi, Indië, 682027
        • Aster Medcity, Aster DM Healthcare Ltd.
    • Gujarat
      • Surat, Gujarat, Indië, 395002
        • Surat Institute of Digestive Sciences
    • Haryana
      • Gurugram, Haryana, Indië, 122002
        • Fortis Memorial Research Institute
    • Maharashtra
      • Nagpur, Maharashtra, Indië, 440010
        • Midas Multispeciality Hospital Pvt. Ltd
    • Rajasthan
      • Jaipur, Rajasthan, Indië, 302001
        • S. R. Kalla Memorial Gastro & General Hospital
      • Afula, Israël, 1834111
        • Haemek Medical Center
      • Jerusalem, Israël, 9103102
        • Shaare Zedek Medical Center
      • Ramat Gan, Israël, 5262000
        • Chaim Sheba Medical Center
      • Tel Aviv, Israël, 6423906
        • Tel Aviv Sourasky Medical Center
      • Catania, Italië, 829-95126
        • Azienda Ospedaliera Ospedale Cannizzaro
      • Catanzaro, Italië, 88100
        • A.O. Mater Domini, U.O. Fisiopatologia Apparato Digerente Campus Universitario "Salvatore Venuta"
      • Catanzaro, Italië, 88100
        • A.O. Mater Domini, U.O. Fisiopatologia Apparato Digerente
      • Catanzaro, Italië, 88100
        • CAMPUS GERMANETO Magazzino farmaci e dispositivi medici, uffici
      • Pavia, Italië, 27100
        • Fondazione IRCCS Policlinico San Matteo - Centro per lo Studio e la Cura delle Amiloidosi Sistemiche
      • Rome, Italië, 00189
        • PFT address: Azienda Ospedaliero-Universitaria Sant' Andrea UOC Pneumologia
      • Verona, Italië, 37024
        • IRCCS Ospedale Sacro Cuore Don Calabria
      • Verona, Italië, 37134
        • OCT/PFT/Endoscopy address: CRC - Cenro Ricerche Cliniche di Verona
    • Foggia
      • San Giovanni Rotondo, Foggia, Italië, 71013
        • IRCCS Ospedale Casa Sollievo della Sofferenza
      • San Giovanni Rotondo, Foggia, Italië, 71013
        • OCT/ PFT/ Endoscopy address: IRCCS Ospedale Casa Sollievo della Sofferenza
    • MI
      • Milan, MI, Italië, 20132
        • Ospedale San Raffaele
    • Milan
      • Garbagnate Milanese, Milan, Italië, 20024
        • ASST Rhodense - Pneumology Unit
      • Milan, Milan, Italië, 20017 Rho
        • ASST Rhodense, U.O.C. Gastroenterologia ed Endoscopia Digestiva
      • Rho, Milan, Italië, 20017
        • ASST Rhodense - Ophthalmology Unit
    • Milano
      • Rozzano, Milano, Italië, 20089
        • Irccs Humanitas Research Hospital
    • Verona
      • Negrar, Verona, Italië, 37024
        • OCT/ PFT/ Endoscopy address: IRCCS Ospedale Sacro Cuore Don Calabria
    • Chiba
      • Kashiwa-shi, Chiba, Japan, 277-0871
        • Kokikai Tsujinaka Hospital Kashiwanoha
      • Nagareyama-shi, Chiba, Japan, 270-0116
        • Ishii Eye Clinic
    • Fukuoka
      • Kitakyushu-shi, Fukuoka, Japan, 807-8555
        • Hospital of the University of Occupational and Environmental Health
      • Kitakyusyu-shi, Fukuoka, Japan, 802-8561
        • Kitakyushu Municipal Medical Center
    • Ibaraki
      • Toride-shi, Ibaraki, Japan, 302-0014
        • Matsumoto Eye Clinic
    • Kagoshima-ken
      • Kagoshima, Kagoshima-ken, Japan, 892-0846
        • Sameshima Hospital
      • Kagoshima, Kagoshima-ken, Japan, 892-0824
        • Jiaikai Idzuro Imamura Hospital
      • Kagoshima, Kagoshima-ken, Japan, 890-0062
        • Kagoshima Kouseiren Hospital
      • Kagoshima, Kagoshima-ken, Japan, 892-0825
        • Sameshima Eye Clinic
    • Kumamoto
      • Kumamoto, Kumamoto, Japan, 861-8520
        • Japanese Red Cross Kumamoto Hospital
    • Saga-ken
      • Saga, Saga-ken, Japan, 849-8501
        • Saga University Hospital
    • Tokyo
      • Shinjuku-ku, Tokyo, Japan, 169-0073
        • Japan Community Health Care Organization Tokyo Yamate Medical Center
      • Zagreb, Kroatië, 10000
        • University Hospital Center Zagreb
      • Beirut, Libanon, 166830
        • Hotel Dieu de France Hospital
      • Beirut, Libanon, 1100 2807
        • Saint George University Hospital Medical Center
      • Beirut, Libanon, 113-6044
        • Rafik Hariri University Hospital
      • Saida, Libanon
        • Hammoud Hospital University Medical Center
      • Tripoli, Libanon
        • Nini Hospital s.a:l
      • Vilnius, Litouwen, LT-08661
        • Vilnius University Hospital Santaros Klinikos
      • Kuala Lumpur, Maleisië, 59100
        • University Malaya Medical Centre
      • Chihuahua City, Mexico, 31203
        • Scientia Investigacion Clinica S.C.
      • Chihuahua City, Mexico, 31020
        • Sanatorio Palmore A.C.
      • Chihuahua City, Mexico, 31203
        • Vista Lasser de Chihuahua S.C.
      • Chihuahua City, Mexico, 31283
        • Servicios Hospitalarios de México, S.A. de C.V.
      • Veracruz, Mexico, 91900
        • FAICIC S. de R.L. de C.V.
      • Veracruz, Mexico, 91910
        • Gabinete de Diagnostico COVADONGA
      • Veracruz, Mexico, 91918
        • Alberto Collado Solorzano (Clinica Vision)
    • Jalisco
      • Guadalajara, Jalisco, Mexico, 44130
        • Centro de Investigacion Medico Biologica Y Terapia Avanzada S.C.
      • Guadalajara, Jalisco, Mexico, 44600
        • Global Glaucoma Institute
      • Guadalajara, Jalisco, Mexico, 44600
        • Video Endoscopia Americas
      • Guadalajara, Jalisco, Mexico, 44670
        • Comercializadora Winco S.A. de C.V.
    • Veracruz
      • Boca del Rio, Veracruz, Mexico, 94299
        • Cirugia y Gastro de Veracruz S.A. de C.V. (Progastro)
      • Chisinau, Moldavië, 2005
        • "Sf. Arhanghel Mihail" Municipal Clinical Hospital, Department of Gastroenterology
      • Chisinau, Moldavië, MD2025
        • PMSI Republican Clinical Hospital "Timofei Mosneaga", Department of Colorectal Surgery
      • Chisinau, Moldavië, MD2025
        • PMSI Republican Clinical Hospital "Timofei Mosneaga", Department of Gastroenterology
      • Chisinau, Moldavië, MD2025
        • PMSI Republican Clinical Hospital "Timofei Mosneaga", Outpatient Department
      • Amsterdam, Nederland, 1105 AZ
        • Academic Medical Centre
      • Utrecht, Nederland, 3584 CX
        • UMC Utrecht
      • Kharkiv, Oekraïne, 61124
        • Communal Non-commercial Enterprise City Clinical Hospital #13 of Kharkiv City Council
      • Kharkiv, Oekraïne, 61024
        • LLC "EyeQClinic"
      • Kharkiv, Oekraïne, 61022
        • Llc "Ldts Skaymed'
      • Kharkiv, Oekraïne, 61037
        • Communal Non-commercial Enterprise Prof. O.O. Shalimov City Clinical Hospital #2 of Kharkiv
      • Kharkiv, Oekraïne, 61045
        • Llc "Medical Center Oftalmika"
      • Kharkiv, Oekraïne, 61103
        • Municipal Health Care "Kharkiv City Hospital Ambulance and Emergency Medical care
      • Kyiv, Oekraïne, 01135
        • Medical Center of Limited Liability Company Harmoniia Krasy
      • Kyiv, Oekraïne, 02091
        • Med Center 'Ok!Clinic+' of Comp with limited liability "Int Inst of Clin Research", Unit of Gastro
      • Kyiv, Oekraïne, 04210
        • Private Enterprise "Clinic Medicom"
      • Lutsk, Oekraïne, 43005
        • CE Volyn Reg Clinical Hospital ofVolyn Reg Council, Surgical (Endocrine and Abdominal Pathology)
      • Vinnytsia, Oekraïne, 21000
        • Private Enterprise Diagnostic Center "Mediscan"
      • Vinnytsia, Oekraïne, 21009
        • Medical Center of LLC Health Clinic, Medical Clinical Research Center, Unit of Gastroenterology,
      • Vinnytsia, Oekraïne, 21018
        • CNE of M.I. Pyrohov Vinnytsia Regional Clinical Hospital of Vinnytsia Regional Council, Reg
      • Vinnytsia, Oekraïne, 21029
        • Scientific and Research Institute of Invalid Rehabilitation (Educational, Scientific and Treatment
      • Graz, Oostenrijk, 8036
        • LKH Universitats-Klinikum Graz
      • Innsbruck, Oostenrijk, A-6020
        • Medical University Innsbruck, Internal Medicine Ⅰ
      • Vienna, Oostenrijk, 1090
        • AKH Wien- Universitatsklinik fiir Innere Medizin III
      • Vienna, Oostenrijk, 1090
        • Univ.-Professor Dr. Mehrdad Baghestanian
      • Vienna, Oostenrijk, 1090
        • AKH Wien- Universitatsklinik fur Innere Medizin III
      • Bystra, Polen, 43-360
        • Centrum Pulmonologii i Torakochirurgii w Bystrej (DLCO)
      • Karkow, Polen, 31-156
        • Specjalistyczne Gabinety Lekarskie LANDA
      • Krakow, Polen, 30-033
        • Centre De La Vision Centrum Okulistyczne(OCT, Ophthalmoscopy)
      • Krakow, Polen, 30-307
        • Medicina (Endoscopy)
      • Krakow, Polen, 31-153
        • Centrum Medyczne EVITA(Endoscopy)
      • Lodz, Polen, 90-752
        • IP Clinic Sp. z o.o.
      • Lodz, Polen, 90-338
        • Centrum Medyczne "Ksiezy Mlyn" (OCT, Ophtalmoscopy)
      • Lodz, Polen, 93-513
        • Wojewodzkie Wielospecjalistyczne Centrum Onkologii i Traumatolog i im. M. Kopernika w Lodzi
      • Lodz, Polen, 90-338
        • (Centrum Medyczne Ksiezy Mlyn (OCT and Ophthalmoscopy)
      • Lodz, Polen, 90-644
        • AMICARE Sp. z o.o. sp.k
      • Lodz, Polen, 91-053
        • Centra Medyczne Medyceusz (DLCO)
      • Lodz, Polen, 92-551
        • Salve Health Care Sp. o.o., (PFT and Endoscopy)
      • Nowy Targ, Polen, 34-400
        • Allmedica Badania Kliniczne Sp. z o.o. Sp. k.
      • Oświęcim, Polen, 32-600
        • Medicome Sp. Z O.O
      • Piotrkow Trybunalski, Polen, 97-300
        • Przychodnia Okulistyczna "Oculus" Barbara Cybulska (OCT, Ophtalmoscopy)
      • Piotrkow Trybunalski, Polen, 97-300
        • Samodzielny Szpital Wojewodzki im. Mikolaja Kopernika (Endoscopy)
      • Piotrokow Trybunalski, Polen, 97-300
        • Trialmed CRS
      • Poznan, Polen, 60-529
        • Solurmed Centrum Medyczne
      • Poznan, Polen, 60-538
        • OCU Service Mikolaj Meller Sp.j.(OCT, Ophtalmoscopy)
      • Rzeszów, Polen, 35-326
        • Centrum Medyczne Medyk
      • Rzeszów, Polen, 35-055
        • Kliniczny Szpital Wojewodzki Nr 1 im. Fryderyka Chopina w Rzeszowie (Ophthalmpscopy)
      • Rzeszów, Polen, 35-241
        • Podkarpackie Centrum Chorob Plue w Rzeszowie (DLCO)
      • Strzegom, Polen, 58-150
        • Strzegomskie Centrum Medyczno - Diagnostyczne Sp. z o.o. (Endoscopy)
      • Swidnica, Polen, 58-100
        • DC-MED
      • Swidnica, Polen, 58-100
        • Centrum Medyczne EZ-MEDICA (OCT, Ophtalmoscopy)
      • Swidnica, Polen, 58-100
        • Szpital "Latawiec" -Poradnia Gruzlicy i Chorob Pluc (PFT)
      • Warsaw, Polen, 00-635
        • Centrum Zdrowia MDM
      • Warsaw, Polen, 00-631
        • Centrum Zdrowia MDM (OCT,opthalmoscopy)
      • Warsaw, Polen, 01-138
        • Instytut Gruzlicy i Chorob Pluc(DLCO)
      • Warsaw, Polen, 02-653
        • Endoterapia PFG (Endoscopy)
      • Warsaw, Polen, 02-653
        • Instytut Oka (OCT, Ophtalmoscopy)
      • Warsaw, Polen, 03-712
        • Specjalistyczne Gabinety Lekarskie Body Clinic
      • Warsaw, Polen, 03-731
        • Centrum Okulistyczne JASKRA (OCT, Ophthalmoscopy)
      • Warsaw, Polen, 04-141
        • Wojskowy lnstytut Medyczny (PFT)
      • Wroclaw, Polen, 60-681
        • EuroMediCare Szpital Specjalistyczny z Przychodniit (Endoscopy)
    • Greater Poland Voivodeship
      • Poznan, Greater Poland Voivodeship, Polen, 60-681
        • NSZOZ Termedica
      • Bucharest, Roemenië, 012015
        • SC Centrul Medical Medicum SRL, Specialitatea Gastroenterologie
      • Bucharest, Roemenië, 022328
        • Institutul Clinic Fundeni, Centrul de Gastroenterologie si Hepatologie
    • JUD. CLUJ
      • Cluj-Napoca, JUD. CLUJ, Roemenië, 400006
        • Spitalul Clinic Judetean de Urgenta Cluj Napoca
    • Jud.constanta
      • Constanța, Jud.constanta, Roemenië, 900591
        • Centrul de Diagnostic si Tratament Affidea, Specialitatea Medicina Interna
      • Kemerovo, Rusland, 650066
        • SAIH "Kemerovo Regional Clinical Hospital"
      • Novosibirsk, Rusland, 630005
        • LLC "SibNovoMed"
      • Novosibirsk, Rusland, 630007
        • Gastrocenter
      • Novosibirsk, Rusland, 630007
        • LLC "Novosibirskiy Gastrocentr''
      • Novosibirsk, Rusland, 630084
        • Hospital #12
      • Novosibirsk, Rusland, 630091
        • LLC "Siberian Center for Prevention and Treatment of Myopia Eye"
      • Novosibirsk, Rusland, 630099
        • Joint Stock Company Medical Center "AVICENNA"
      • Omsk, Rusland, 644013
        • BHI of Omsk region "Clinical Oncology Dispensary"
      • Omsk, Rusland, 644024
        • Clinicodiagnostic Center "Ultramed"
      • Omsk, Rusland, 644070
        • Medical center "Intervzglyad"
      • Saint Petersburg, Rusland, 191015
        • FSBI of Higher Education " North-Western Medical University n.a.I.I. Mechnikov '' of MoH RF
      • Saint Petersburg, Rusland, 195067
        • FSBI of Higher Education "North-Western Medical University n.a.I.I. Mechnikov'' of MoH RF
      • Stavropol, Rusland, 355017
        • Autonomous Noncommercial Medical Organization "Stavropol Regional Clinical
    • Stavropol Kray
      • Pyatigorsk, Stavropol Kray, Rusland, 357502
        • LLC "Polyclinic of ultrasonography 4D"
      • Belgrade, Servië, 11000
        • Clinical Center Zvezdara
      • Banská Bystrica, Slowakije, 975 17
        • Fakultna nemocnica s poliklinikou F.D.Roosevelta
      • Bardejov, Slowakije, 08501
        • ALIAN. s.r.o .. Ambulancia vnutorneho lekarstva
      • Košice, Slowakije, 040 13
        • ENDOMED, s.r.o. Gastroenterologicka ambulancia
      • Lipany, Slowakije, 082 71
        • Opthalmology outpatient clinic, MUDr. Michal Popovec, s.r.o.
      • Nitra, Slowakije, 949 01
        • KM Management spol.s.r.o. Gastroenterologicke a hepatologicke centrum
      • Prešov, Slowakije, 080 01
        • GASTRO LM s.r.o., Gastroenterologicka ambulancia
      • Prešov, Slowakije, 080 01
        • Pneumology: PULMO, s.r.o.
      • Las Palmas de Gran Canaria, Spanje, 35010
        • Hospital Universitario de Gran Canaria Dr. Negrín
      • Madrid, Spanje, 28046
        • Hospital Universitario La Paz
    • Ciudad REAL
      • Tomellso, Ciudad REAL, Spanje, 13700
        • Hospital General de Tomelloso
      • Horažďovice, Tsjechië, 341 01
        • MUDr. Jaroslava Skalova
      • Hradec Králové, Tsjechië, 500 12
        • Hepato-gastroenterologie HK, s.r.o.
      • Hradec Králové, Tsjechië, 500 12
        • VISUS, spol s.r.o.
      • Klatovy, Tsjechië, 339 01
        • GASTRO JeKa, s.r.o.
      • Klatovy, Tsjechië, 339 01
        • Klatovska nemocnice a.s.
      • Olomouc, Tsjechië, 779 00
        • PreventaMed s.r.o.
      • Olomouc, Tsjechië, 779 00
        • Ocni ordinace Olomouc
      • Olomouc, Tsjechië, 779 00
        • MUDr. Pavlina Kazinotova s.r.o.
      • Ankara, Turkije (Türkiye), 06500
        • Gazi University Medical Faculty
      • Ankara, Turkije (Türkiye), 06100
        • Hacettepe University Medical Faculty
      • Ankara, Turkije (Türkiye), 06800
        • T.C. Saglik Bakanligi Ankara Sehir Hastanesi
      • Antalya, Turkije (Türkiye), 07100
        • Saglik Bilimleri Universitesi Antalya Egitim ve Arastirma Hastanesi
      • Izmir, Turkije (Türkiye), 35100
        • Ege Universitesi Tip Fakultesi Hastanesi
      • Kocaeli, Turkije (Türkiye), 41380
        • Kocaeli University Research and Training Hospital
      • Yenişehir, Turkije (Türkiye), 33343
        • Mersin University Faculty of Medicine
      • Liverpool, Verenigd Koninkrijk, L7 8XP
        • Royal Liverpool University Hospital
      • London, Verenigd Koninkrijk, SE1 9RT
        • Guys & St Thomas Hospital
      • Norwich, Verenigd Koninkrijk, NR4 7UQ
        • Quadram Institute Clinical Research Facility
    • Alabama
      • Dothan, Alabama, Verenigde Staten, 36301
        • Digestive Health Specialists
      • Dothan, Alabama, Verenigde Staten, 36301
        • Dothan Eyecare-Dr. Brent McKinley (OCT Location)
      • Dothan, Alabama, Verenigde Staten, 36301
        • Center for Digestive Health (Endoscopy Location)
      • Dothan, Alabama, Verenigde Staten, 36301
        • Pulmonary Associates (PFT Location)
      • Dothan, Alabama, Verenigde Staten, 36305
        • Flowers Hospital (Imaging Location)
      • Mobile, Alabama, Verenigde Staten, 36608
        • Digestive Health Specialists (Satellite Clinic Location)
      • Mobile, Alabama, Verenigde Staten, 36608
        • Premier Medical Group East (Opthalmology & Optometry Facility)
      • Mobile, Alabama, Verenigde Staten, 36608
        • Pulmonary Associates (Chest X-Ray & PFT Facility)
      • Mobile, Alabama, Verenigde Staten, 36608
        • Surgicare of Mobile (Endoscopy & Biopsy Facility)
    • Arizona
      • Peoria, Arizona, Verenigde Staten, 85381
        • Arizona Retina Institute/ Phoenix Retina Associates(OCT)
      • Peoria, Arizona, Verenigde Staten, 85381
        • SimonMed Imaging (Imaging)
      • Sun City, Arizona, Verenigde Staten, 85351
        • Sun City Endoscopy Center (Endoscopy)
    • California
      • Apple Valley, California, Verenigde Staten, 92307
        • Om Research LLC
      • Apple Valley, California, Verenigde Staten, 92307
        • Victor Valley Advanced Imaging
      • La Jolla, California, Verenigde Staten, 92037
        • UCSD lnvestigational Drug Service Pharmacy
      • La Jolla, California, Verenigde Staten, 92093
        • Shiley Eye Institute (OCT)
      • La Jolla, California, Verenigde Staten, 92037
        • Koman Family Outpatient Pavilion (ENDO)
      • La Jolla, California, Verenigde Staten, 92037
        • Perlman Medical Offices
      • La Jolla, California, Verenigde Staten, 92037
        • UCSD Clinical and Translational Research Institute
      • La Jolla, California, Verenigde Staten, 92037
        • UCSD Health System (Endo/PFT/DLCO)
      • Lancaster, California, Verenigde Staten, 93534
        • Om Research LLC
      • Lancaster, California, Verenigde Staten, 93534
        • A V Pediatrics, Allergy and Family Medicine - PFT
      • Lancaster, California, Verenigde Staten, 93534
        • Advanced Endoscopy and Pain Center - Colonoscopy
      • Lancaster, California, Verenigde Staten, 93534
        • Advanced Imaging Center - Chest X-Ray
      • Lancaster, California, Verenigde Staten, 93534
        • Antelope Valley Eye Care - Ophthalmologist
      • Lancaster, California, Verenigde Staten, 93534
        • AV Pediatrics Allergy and Family Medicine
      • Lancaster, California, Verenigde Staten, 93534
        • Jatinder S. Pruthi, MD FACG CPI
      • Murrieta, California, Verenigde Staten, 92563
        • United Medical Doctors
      • Victorville, California, Verenigde Staten, 92392
        • Retina Consultants of Southern California
      • Victorville, California, Verenigde Staten, 92395
        • Physicians Surgery Center
    • Colorado
      • Colorado Springs, Colorado, Verenigde Staten, 80907
        • Peak Gastroenterology Associates
      • Colorado Springs, Colorado, Verenigde Staten, 80903
        • Front Range Endoscopy Center
      • Colorado Springs, Colorado, Verenigde Staten, 80909
        • Colorado Springs Pulmonary Consultants, PC
      • Colorado Springs, Colorado, Verenigde Staten, 80909
        • The Wright Eye Center (OCT Facility)
      • Colorado Springs, Colorado, Verenigde Staten, 80919
        • Colorado Springs Imaging (Ultrasound and MRE Location)
    • Florida
      • Boca Raton, Florida, Verenigde Staten, 33487
        • Xera Med Research
      • Boynton Beach, Florida, Verenigde Staten, 33472
        • RecioMed Clinical Research Network, Inc
      • Brandon, Florida, Verenigde Staten, 33511
        • Florida Advanced Gastroenterology Center - Rahman Nakshabendi MD and Imad Nakshabendi, MD
      • Clearwater, Florida, Verenigde Staten, 33756
        • West Coast Endoscopy Center (Endoscopy Procedures)
      • Clearwater, Florida, Verenigde Staten, 33756
        • Bay Area Chest Physicians, P.A. (Pulmonary Function Test)
      • Clearwater, Florida, Verenigde Staten, 33761
        • Northwood Vision (Optical Coherence Tomography)
      • Clearwater, Florida, Verenigde Staten, 33761
        • Safety Harbor Surgery (Endoscopy Procedures)
      • Clearwater, Florida, Verenigde Staten, 33762
        • Gastro Florida (Regulatory Administrative Duties)
      • Coral Gables, Florida, Verenigde Staten, 33134
        • Beraja Medical Institute (OCT)
      • Hialeah, Florida, Verenigde Staten, 33012
        • Advanced Eye Center
      • Jacksonville, Florida, Verenigde Staten, 32256
        • Encore Borland-Groover Clinical Research
      • Jacksonville, Florida, Verenigde Staten, 32207
        • UF Health Imaging Center-Emerson (chest x-rays)
      • Jacksonville, Florida, Verenigde Staten, 32207
        • UF Health Laboratory Emerson (blood draws)
      • Jacksonville, Florida, Verenigde Staten, 32209
        • UF Health Jacksonville Respiratory Therapy (PFT and DLCO)
      • Jacksonville, Florida, Verenigde Staten, 32209
        • UF Health Jacksonville-Faculty Clinic (ileocolonoscopy and biopsy)
      • Jacksonville, Florida, Verenigde Staten, 32209
        • UF Health Opthalmology - Jacksonville (Ophthalmology with OCT)
      • Jacksonville, Florida, Verenigde Staten, 32209
        • UF Health Radiology-Jacksonville (chest x-rays)
      • Jacksonville, Florida, Verenigde Staten, 32216
        • Cisca Pulmonary & Critical Care (PFT Facility)
      • Jacksonville, Florida, Verenigde Staten, 32216
        • Nicolitz Eye Consultants (OCT Facility)
      • Jacksonville, Florida, Verenigde Staten, 32256
        • Borland-Groover Clinic (Endoscopy Facility)
      • Jupiter, Florida, Verenigde Staten, 33458
        • Jupiter Outpatient Surgery Center
      • Kissimmee, Florida, Verenigde Staten, 34741
        • IHS Health, LLC
      • Largo, Florida, Verenigde Staten, 33773
        • Lee Shettle Eye & Hearing (Ophthalmoscopy Only)
      • Miami, Florida, Verenigde Staten, 33133
        • Infinite Clinical Research
      • Miami, Florida, Verenigde Staten, 33156
        • Research Associates of South Florida
      • Miami, Florida, Verenigde Staten, 33176
        • Anchor Medical Research, LLC
      • Miami, Florida, Verenigde Staten, 33134
        • The Endoscopy Center (Endoscopy Procedure)
      • Miami, Florida, Verenigde Staten, 33173
        • Juan Barrio, MD (PFT when needed)
      • Miami, Florida, Verenigde Staten, 33133
        • Pulmonology Physicians of South Florida
      • Miami, Florida, Verenigde Staten, 33133
        • Reina Eye Care P.A.
      • Miami, Florida, Verenigde Staten, 33155
        • La Salud Research Clinic Inc.
      • Miami, Florida, Verenigde Staten, 33156
        • South Florida Center for Endoscopy and Digestive Disease, LLC
      • Naples, Florida, Verenigde Staten, 34102
        • Gastroenterology Group of Naples
      • Naples, Florida, Verenigde Staten, 34102
        • Gulfshore Endoscopy Center
      • Naples, Florida, Verenigde Staten, 34103
        • Retina Consultants of Southwest Florida OCT only
      • Naples, Florida, Verenigde Staten, 34109
        • Lisette Delgado Sanchez, MD PFT only
      • Orlando, Florida, Verenigde Staten, 32825
        • Pediatric & Adult Research Center
      • Palmetto Bay, Florida, Verenigde Staten, 33157
        • IMIC Inc.
      • Palmetto Bay, Florida, Verenigde Staten, 33157
        • IMIC Inc
      • Port Orange, Florida, Verenigde Staten, 32127
        • Advanced Medical Research Center
      • Seminole, Florida, Verenigde Staten, 33777
        • Bardmoor GastroEnterology
      • South Miami, Florida, Verenigde Staten, 33143
        • Larkin Community Hospital (Endoscopy Procedure)
      • St. Petersburg, Florida, Verenigde Staten, 33705
        • St. Petersburg Endoscopy Center (Endoscopy Procedures)
      • St. Petersburg, Florida, Verenigde Staten, 33707
        • Pasadena Center for Asthma and Lung Disorders (PFT and DLCO Only)
      • St. Petersburg, Florida, Verenigde Staten, 33709
        • Bay Area Endoscopy and Surgery Center (Endoscopy only)
      • St. Petersburg, Florida, Verenigde Staten, 33709
        • Theia Clinical Research, LLC
      • St. Petersburg, Florida, Verenigde Staten, 33710
        • Advanced Research Institute Inc.(IP and PFT)
      • Sun City Center, Florida, Verenigde Staten, 33573
        • Absolute Surgical Specialist - Craig Amshel, MD
      • Tampa, Florida, Verenigde Staten, 33612
        • USF Health Morsani Center for Advanced Healthcare
      • Tampa, Florida, Verenigde Staten, 33606
        • USF Health South Tampa Center for Advanced Healthcare
      • Tampa, Florida, Verenigde Staten, 33609
        • GCP Clinical Research,LLC
      • Tampa, Florida, Verenigde Staten, 33609
        • South Tampa Surgery Center
      • Tampa, Florida, Verenigde Staten, 33609
        • Newsome Eye Specialist (OCT Procedures Only)
      • Tampa, Florida, Verenigde Staten, 33606
        • Lab - Processing/ Storage
      • Tampa, Florida, Verenigde Staten, 33609
        • LoCicero Medical Group
    • Georgia
      • Atlanta, Georgia, Verenigde Staten, 30342
        • Atlanta Gastroenterology Associates
      • Atlanta, Georgia, Verenigde Staten, 30309
        • Digestive Healthcare of Georgia
      • Atlanta, Georgia, Verenigde Staten, 30324
        • Ross Eyecare - Opthalmoscopy and OCT
      • Atlanta, Georgia, Verenigde Staten, 30342
        • Atlanta Gastroenterology Associates (endoscopy only)
      • Atlanta, Georgia, Verenigde Staten, 30342
        • Atlanta Gastroenterology Associates(IP only)
      • Atlanta, Georgia, Verenigde Staten, 30309
        • Peachtree Allergy and Asthma Clinic - Chest X-rays and PFTs
    • Illinois
      • Arlington Heights, Illinois, Verenigde Staten, 60005
        • GI Alliance
      • Arlington Heights, Illinois, Verenigde Staten, 60005
        • Northwest Endoscopy Center (Endoscopy)
      • Gurnee, Illinois, Verenigde Staten, 60031
        • GI Alliance (PFT)
      • Gurnee, Illinois, Verenigde Staten, 60031
        • Illinois Gastroenterology Group-Gurnee (Patients Seen; IP Delivered)
      • Gurnee, Illinois, Verenigde Staten, 60031
        • Medical Eye Services LTD (Ophthalmoscopy with OCT)
      • Lake Bluff, Illinois, Verenigde Staten, 60044
        • North Shore Endoscopy Center (Endoscopy)
      • Libertyville, Illinois, Verenigde Staten, 60048
        • Libertyville Imaging Center (Diagnostic Imaging)
      • Morton Grove, Illinois, Verenigde Staten, 60053
        • 3T Imaging of Morton Grove (Diagnostic Imaging)
    • Maryland
      • Columbia, Maryland, Verenigde Staten, 21045
        • Cascades Endoscopy Center
      • Columbia, Maryland, Verenigde Staten, 21044
        • Charter Radiology
      • Columbia, Maryland, Verenigde Staten, 21045
        • Gastro Center of Maryland, LLC
      • Hanover, Maryland, Verenigde Staten, 21076
        • Kaylani Eye Care ( Optical Coherence Tomography and Opthalmoscopy only)
      • Laurel, Maryland, Verenigde Staten, 20707
        • Lung Center (Pulmonary Function Test only)
    • Mississippi
      • Jackson, Mississippi, Verenigde Staten, 39216
        • Southern Therapy and Advanced Research, LLC
      • Jackson, Mississippi, Verenigde Staten, 39216
        • A Terrell Williams, MD, PLLC (OCT)
      • Jackson, Mississippi, Verenigde Staten, 39216
        • Jackson Pulmonary Associates (PFT)
      • Jackson, Mississippi, Verenigde Staten, 39216
        • St. Dominic Ambulatory Surgery Center (colonoscopy, Endoscopy)
    • Missouri
      • Creve Coeur, Missouri, Verenigde Staten, 63141
        • Barnes-Jewish West County Hospital (Additional Endoscopy Location)
      • St Louis, Missouri, Verenigde Staten, 63110
        • Barnes-Jewish Hospital
      • St Louis, Missouri, Verenigde Staten, 63110
        • Washington University School of Medicine
      • St Louis, Missouri, Verenigde Staten, 63108
        • Washington University School of Medicine
    • New Jersey
      • Freehold, New Jersey, Verenigde Staten, 07728
        • Allied Health Clinical Research Organization, LLC
      • Freehold, New Jersey, Verenigde Staten, 07728
        • Freehold Endoscopy Associates, LLC d/b/a Endoscopy Center of Monmouth County
      • Freehold, New Jersey, Verenigde Staten, 07728
        • Freehold Ophthalmology
      • Freehold, New Jersey, Verenigde Staten, 07728
        • Monmouth Ocean Pulmonary Medicine
      • Freehold, New Jersey, Verenigde Staten, 07728
        • Princeton Radiology
    • New York
      • New York, New York, Verenigde Staten, 10016
        • NYU Langone Health
      • New York, New York, Verenigde Staten, 10016
        • NYU Langone Inflammatory Bowel Disease Center
      • New York, New York, Verenigde Staten, 10016
        • NYU Langone Eye Center (Ophthalmology)
      • New York, New York, Verenigde Staten, 10016
        • NYU Langone Health - Ambulatory Care Center
      • New York, New York, Verenigde Staten, 10016
        • NYU Langone Health, Investigational Pharmacy, Perlmutter Cancer Center
      • New York, New York, Verenigde Staten, 10016
        • NYU Pulmonary and Critical Care Associates (Pulmonary)
    • North Carolina
      • Charlotte, North Carolina, Verenigde Staten, 28215
        • Carolinas Research Center
      • Charlotte, North Carolina, Verenigde Staten, 28204
        • Queen City Gastroenterology and Hepatology (Endoscopy)
      • Charlotte, North Carolina, Verenigde Staten, 28211
        • Greenman Eye Associates (OCT)
      • Charlotte, North Carolina, Verenigde Staten, 28273
        • Cornerstone Medical (Imaging & PFT)
    • Ohio
      • Chardon, Ohio, Verenigde Staten, 44024
        • Geauga Sleep Center(PFT only)
      • Cincinnati, Ohio, Verenigde Staten, 45219
        • UC Health Physicians Office
      • Cincinnati, Ohio, Verenigde Staten, 45229
        • UC Health (Pulmonary Function Testing)
      • Cincinnati, Ohio, Verenigde Staten, 45219
        • UC Health Hoxworth (OCT only)
      • Cincinnati, Ohio, Verenigde Staten, 45219
        • University of Cincinnati Medical Center (PFT and Endoscopy location)
      • Mentor, Ohio, Verenigde Staten, 44060
        • Great Lakes Gastroenterology Research, LLC
      • Mentor, Ohio, Verenigde Staten, 44060
        • The Endoscopy Center of Lake County
      • Mentor, Ohio, Verenigde Staten, 44060
        • Ophthalmic Physicians Incorporated (OCT Only)
      • Mentor, Ohio, Verenigde Staten, 44060
        • Vitreo Retinal Consultants(OCT only)
      • Willoughby, Ohio, Verenigde Staten, 44094
        • Lake Pulmonary Associates (PFT only)
      • Willoughby Hills, Ohio, Verenigde Staten, 44094
        • Retina Specialists of Ohio(OCT only)
    • Oklahoma
      • Norman, Oklahoma, Verenigde Staten, 73071
        • Norman Endoscopy Center
      • Norman, Oklahoma, Verenigde Staten, 73071
        • Physicians and Surgeons X-Ray
      • Oklahoma City, Oklahoma, Verenigde Staten, 73118
        • Central Sooner Research
      • Oklahoma City, Oklahoma, Verenigde Staten, 73102
        • Hightower Clinical
      • Oklahoma City, Oklahoma, Verenigde Staten, 73102
        • Saint Anthony Endoscopy Center
      • Oklahoma City, Oklahoma, Verenigde Staten, 73102
        • SSM Health, Saint Anthony Hospital
      • Oklahoma City, Oklahoma, Verenigde Staten, 73120
        • Johnston Opthalmology
    • Pennsylvania
      • Hershey, Pennsylvania, Verenigde Staten, 17033
        • Penn State Milton S. Hershey Medical Center
    • Texas
      • Austin, Texas, Verenigde Staten, 78705
        • Central Texas Clinical Research
      • Cypress, Texas, Verenigde Staten, 77429
        • Houston Pulmonary Sleep and Allergy Associates (PFT)
      • Houston, Texas, Verenigde Staten, 77030
        • The University of Texas Health Science Center at Houston
      • Houston, Texas, Verenigde Staten, 77030
        • Baylor St. Luke's Medical Center
      • Houston, Texas, Verenigde Staten, 77047
        • Pearland Surgery Center
      • Houston, Texas, Verenigde Staten, 77030
        • Alkek Eye Center Jamail Specialty Care Center (OCT)
      • Houston, Texas, Verenigde Staten, 77024
        • Houston Eye Associates (For Eye Examination)
      • Houston, Texas, Verenigde Staten, 77030
        • Baylor College of Medicine - Baylor St. Luke's Medical Center
      • Houston, Texas, Verenigde Staten, 77030
        • Baylor St. Luke's Medical Center - McNair Campus (pharmacy)
      • Houston, Texas, Verenigde Staten, 77030
        • Baylor St. Luke's Medical Center - McNair Campus
      • Houston, Texas, Verenigde Staten, 77030
        • Baylor St. Luke's Medical Center Endoscopy - McNair Campus
      • Houston, Texas, Verenigde Staten, 77030
        • Mann Eye Institute
      • Houston, Texas, Verenigde Staten, 77030
        • Memorial Hermann Hospital- TMC Investigational Drugs Services Pharmacy (Drug Storage)
      • Houston, Texas, Verenigde Staten, 77034
        • Bay Area Endoscopy Center, LLC
      • Houston, Texas, Verenigde Staten, 77055
        • Memorial Endoscopy Center (For Colonoscopy)
      • Houston, Texas, Verenigde Staten, 77065
        • Eye Specialists of Texas
      • Houston, Texas, Verenigde Staten, 77065
        • Northside Gastroenterology Associates PA
      • Houston, Texas, Verenigde Staten, 77079
        • Memorial Pulmonology(For PFT)
      • Houston, Texas, Verenigde Staten, 77204
        • Digestive Health Associates
      • Houston, Texas, Verenigde Staten, 77204
        • Memorial Hermann Memorial City Digestive Health Center (For Colonoscopy)
      • Pearland, Texas, Verenigde Staten, 77584
        • LinQ Research, LLC
      • Tyler, Texas, Verenigde Staten, 75701
        • Tyler Research Institute, LLC
      • Tyler, Texas, Verenigde Staten, 75701
        • UT Health East Texas Physicians (pulmonary functions only)
      • Tyler, Texas, Verenigde Staten, 75701
        • Christus Trinity Mother Frances Endoscopy Center (endoscopies only)
      • Tyler, Texas, Verenigde Staten, 75701
        • Heaton Eye Associates (OCT only)
      • Victoria, Texas, Verenigde Staten, 77904
        • Victoria Gastroenterology
      • Victoria, Texas, Verenigde Staten, 77904
        • Citizens Healthplex (for PFT only)
      • Victoria, Texas, Verenigde Staten, 77904
        • Surgery Center (For endoscopy only)
      • Victoria, Texas, Verenigde Staten, 77904
        • Victoria Eye Center (For OCT only)
      • Webster, Texas, Verenigde Staten, 77598
        • GI Alliance Webster
    • Virginia
      • Forest, Virginia, Verenigde Staten, 24551
        • Harman Eye Center (OCT only)
      • Lynchburg, Virginia, Verenigde Staten, 24502
        • Blue Ridge Medical Research
      • Lynchburg, Virginia, Verenigde Staten, 24501
        • Lynchburg Pulmonary Associates, Inc. (PFT only)
    • Washington
      • Issaquah, Washington, Verenigde Staten, 98029
        • Swedish Endoscopy Center - Issaquah
      • Seattle, Washington, Verenigde Staten, 98122
        • Swedish Medical Center
      • Seattle, Washington, Verenigde Staten, 98104
        • Swedish Gastroenterology
      • Seattle, Washington, Verenigde Staten, 98104
        • Pacific Northwest Retina
      • Seattle, Washington, Verenigde Staten, 98104
        • Richard Bensinger, MD
      • Seattle, Washington, Verenigde Staten, 98122
        • First Hill Endoscopy Center
      • Seattle, Washington, Verenigde Staten, 98122
        • Pulmonary Function Lab
    • Wisconsin
      • Milwaukee, Wisconsin, Verenigde Staten, 53226
        • Froedtert Memorial Lutheran Hospital
      • Homyel, Wit-Rusland, 246029
        • Institution "Gomel Regional Clinical Hospital"
      • Minsk, Wit-Rusland, 220096
        • Health care Institution "10th City Clinical Hospital"
      • Mogilev, Wit-Rusland, 212018
        • Health Care Institution "Mogilev Hospital #1"
      • Vitebsk, Wit-Rusland, 210037
        • Health Care Institution "Vitebsk Regional Clinical Hospital"
      • Vitebsk, Wit-Rusland, 210604
        • Healthcare Institution "Vitebsk Regional Clinical Specialized Center"
      • Daegu, Zuid -Korea, 41404
        • Kyungpook National University Chilgok Hospital
      • Daegu, Zuid -Korea, 41944
        • Kyungpook National University Hospital
      • Daegu, Zuid -Korea, 41944
        • Endoscopy Facility in kyungpook National University Hospital
      • Daegu, Zuid -Korea, 41944
        • OCT Facility In kyungpook National University Hospital
      • Daegu, Zuid -Korea, 41944
        • PFT Facility in Kyungpook National University Hospital
      • Daejeon, Zuid -Korea, 34943
        • The Catholic University of Korea, Daejeon ST. Mary's Hospital
      • Incheon, Zuid -Korea, 21565
        • Gachon University Gil Medical Center
      • Seongnam-si, Zuid -Korea, 13496
        • CHA University Bundang CHA Hospital
      • Seoul, Zuid -Korea, 06273
        • Gangnam Severance Hospital, Yonsei University Health System
      • Seoul, Zuid -Korea, 06973
        • Chung-Ang University Hospital
      • Seoul, Zuid -Korea, 02447
        • Kyunghee University Medical Center
    • Gyeonggi-do
      • Goyang-si, Gyeonggi-do, Zuid -Korea, 10326
        • Dongguk University Ilsan Hospital
    • Free State
      • Bloemfontein, Free State, Zuid-Afrika, 9301
        • Dr W Simmonds (Gastroenterology Department)
    • Gauteng
      • Benoni, Gauteng, Zuid-Afrika, 1501
        • Worthwhile Clinical Trials
      • Benoni, Gauteng, Zuid-Afrika, 1500
        • Dr K Rahman (OTC and Opthalmoscopy)
      • Benoni, Gauteng, Zuid-Afrika, 1500
        • Lakeview Hospital radiology (Radiology)
      • Benoni, Gauteng, Zuid-Afrika, 1500
        • Worthwhile Clinical trials (PFT)
      • Centurion, Gauteng, Zuid-Afrika, 0157
        • Dr E Meyer & Partners, Centurion Eye Hospital (OTC and Opthalmoscopy)
      • Centurion, Gauteng, Zuid-Afrika, 0157
        • Dr Jorg Reichenberger (Endoscopy)
      • Centurion, Gauteng, Zuid-Afrika, 0157
        • Drs Burger Radiologists Inc (X-ray/CT)
      • Centurion, Gauteng, Zuid-Afrika, 0157
        • Johese Clinical Research, Unitas Hospital
      • Johannesburg, Gauteng, Zuid-Afrika, 2193
        • Wits Clinical Research
      • Kempton Park, Gauteng, Zuid-Afrika, 1619
        • Clinresco Centres (Pty) Ltd
      • Kempton Park, Gauteng, Zuid-Afrika, 1619
        • Burger Radiology (Radiology)
      • Kempton Park, Gauteng, Zuid-Afrika, 1619
        • Dr KJP Lubuya (OCT and Opthalmology)
      • Kempton Park, Gauteng, Zuid-Afrika, 1619
        • Prof O Mwantembe (Endoscopy)
      • Pretoria, Gauteng, Zuid-Afrika, 0002
        • Emmed Research
      • Springs, Gauteng, Zuid-Afrika, 1559
        • Dr K Rahman(OTC and Opthalmoscopy)
      • Sunninghill, Gauteng, Zuid-Afrika, 2196
        • Dr I Moola (Endoscopy)
    • Western Cape
      • Cape Town, Western Cape, Zuid-Afrika, 7405
        • Dr Peter Chapman (PFT + DLCO)
      • Cape Town, Western Cape, Zuid-Afrika, 7441
        • Dr Chris Stander (OCT)
      • Cape Town, Western Cape, Zuid-Afrika, 7441
        • Morton & Partners Radiologists (Radiology)
      • Cape Town, Western Cape, Zuid-Afrika, 7441
        • Spoke Research Inc. Room 109
      • Bern, Zwitserland, 3010
        • Inselspital Bern
      • Bern, Zwitserland, 3012
        • OCT/Ophtalmoscopy: Berner Augenklinik am Lindenhofspital

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar tot 80 jaar (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Beschrijving

Geschiktheidscriteria van toepassing op alle deelonderzoeken:

Inclusiecriteria:

  • Mannen of vrouwen van 18 tot 80 jaar,
  • Mogelijkheid om schriftelijke geïnformeerde toestemming of instemming te geven en om te voldoen aan het schema van protocolbeoordelingen
  • Gediagnosticeerd met de ziekte van Crohn (CD) ≥ 3 maanden
  • Heb matig tot ernstig actieve CD bij screening
  • Aangetoonde ontoereikende respons (d.w.z. primaire non-respons), verlies van respons op of intolerantie voor ≥ 1 van de volgende therapieën voor de behandeling van CD:

    1. Orale corticosteroïden (bijv. prednison of het equivalent hiervan, budesonide)
    2. Immunosuppressiva (bijv. azathioprine [AZA], 6-mercaptopurine [6-MP] of methotrexaat [MTX])
    3. Tumornecrosefactor-alfa (TNFα)-antagonisten (bijv. infliximab, adalimumab, certolizumab pegol of biosimilars)
    4. Integrine-receptorantagonist (bijv. Vedolizumab)
    5. Interleukine-12/-23-antagonist (bijv. ustekinumab)
  • Vrouwtjes die zwanger kunnen worden mogen niet zwanger zijn
  • Vrouwen die zwanger kunnen worden en mannen moeten anticonceptie gebruiken

Uitsluitingscriteria:

  • Voorgeschiedenis van onvoldoende respons (dwz primaire non-respons) op middelen uit ≥ 2 klassen biologische geneesmiddelen die op de markt worden gebracht voor de behandeling van CD (dwz TNFα-antagonisten, interleukine 12/23-antagonisten en integrinereceptorantagonisten).
  • Heb colitis ulcerosa, onbepaalde colitis, microscopische colitis, ischemische colitis, colitis door bestraling, colitis geassocieerd met divertikelziekte, toxische megacolon of actieve infectieuze colitis of test positief voor Clostridioides difficile-toxine bij screening.
  • Functioneel of postoperatief kortedarmsyndroom hebben of aanverwante complicaties die een operatie vereisen of de beoordeling van de werkzaamheid verstoren
  • Chirurgische behandeling gehad voor intra-abdominale abcessen ≤ 8 weken voorafgaand aan randomisatie of chirurgische behandeling voor perianale abcessen ≤ 4 weken voorafgaand aan randomisatie.
  • Had darmresectie ≤ 24 weken voorafgaand aan randomisatie of andere intra-abdominale operaties ≤ 12 weken voorafgaand aan randomisatie.
  • U heeft een ileostoma of een colostoma.

Inclusiecriteria voor Deelonderzoek 3:

- Deelnemers die aan de verlengde introductieperiode van deelonderzoek 1 en deelonderzoek 2 zijn begonnen, moeten het bezoek aan de verlengde introductieweek 6 hebben voltooid

Inclusiecriteria voor deelonderzoek 4:

- Deelnemer moet het bezoek in week 52 van deelonderzoek 3 of het bezoek in week 66 van deelonderzoek A hebben voltooid

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Dubbele

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Placebo-vergelijker: Placebo
Etrasimod-overeenkomende placebo-tablet eenmaal daags via de mond ingenomen.
Experimenteel: Etrasimod dosis A
Dosis A oraal ingenomen, eenmaal daags.
Andere namen:
  • APD334
Dosis B eenmaal daags via de mond ingenomen.
Andere namen:
  • APD334
Experimenteel: Etrasimod dosis B
Dosis A oraal ingenomen, eenmaal daags.
Andere namen:
  • APD334
Dosis B eenmaal daags via de mond ingenomen.
Andere namen:
  • APD334

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Percentage of Participants With Endoscopic Response by Simple Endoscopic Score in Crohn's Disease (SES-CD) at Week 14: SSA
Tijdsspanne: Week 14 of SSA
Endoscopic response: SES-CD score <=4 and at least 2-point reduction from baseline with no subscore >1 or >=50% decrease from study baseline in SES-CD. SES-CD consisted of a composite score based on 4 components: size of ulcers, ulcerated surface, affected surface and presence of narrowing assessed in 5 bowel segments: ileum; right; transverse; left colon and rectum. Size of ulcers score: 0= none, 1= aphthous ulcers, 2= large ulcers and 3= very large ulcers. Ulcerated surface score: 0= none, 1= <10%, 2= 10% - 30% and 3= >30%. Affected surface score: 0= unaffected segment, 1= <50%, 2= 50% - 75%, and 3= >75%. Presence of narrowing score: 0= none, 1= single, can be passed, 2= multiple, can be passed, 3= cannot be passed. Total SES-CD= sum of each component score for all 5 bowel segments and ranged from 0 (no disease) to 60 (severe disease), higher score indicated more severe disease.
Week 14 of SSA
Percentage of Participants With Endoscopic Response by SES-CD at Week 14: SS1
Tijdsspanne: Week 14 of SS1
Endoscopic response: SES-CD score <=4 and at least 2-point reduction from baseline with no subscore >1 or >=50% decrease from study baseline in SES-CD. SES-CD consisted of composite score based on 4 components: size of ulcers, ulcerated surface, affected surface and presence of narrowing assessed in 5 bowel segments: ileum; right; transverse; left colon and rectum. Size of ulcers score: 0= none, 1= aphthous ulcers, 2= large ulcers and 3= very large ulcers. Ulcerated surface score: 0= none, 1= <10%, 2= 10% - 30% and 3= >30%. Affected surface score: 0= unaffected segment, 1= <50%, 2= 50% - 75%, and 3= >75%. Presence of narrowing score: 0= none, 1= single, can be passed, 2= multiple can be passed, 3= cannot be passed. Total SES CD= sum of each component score for all 5 bowel segments and ranged from 0 (no disease)-60 (severe disease), higher score indicated more severe disease. Multiple imputation (MI) method used; percentage calculated based on average response rate from MI datasets.
Week 14 of SS1
Percentage of Participants With Clinical Remission by CDAI at Week 52: SS3 Responder Cohort
Tijdsspanne: Week 52 of study
Clinical remission was considered as CDAI score <150. CDAI was a composite index consisting of a weighted scoring of 8 disease activity variables: number of liquid or soft stools; extent of abdominal pain graded from 0 (none) to 3 (severe); general well-being rating assessed from 0 (generally well) to 4 (terrible); presence of complications; taking diphenoxylate/atropine, loperamide or opiates for diarrhea; presence of an abdominal mass (0 as none, 2 as questionable, 5 as definite); hematocrit (HCT): 47 in men and 42 in women and percentage deviation from standard weight, lower bound -10. Total CDAI score was calculated as the sum of variable scores*weighting factor and ranged from 0 (no disease) to 600 (severe disease), where higher scores indicated more severe disease.
Week 52 of study
Percentage of Participants With Clinical Remission by CDAI at Week 52: SS3 Non-Responder Cohort
Tijdsspanne: Week 52 of study
Clinical remission was considered as CDAI score <150. CDAI was a composite index consisting of a weighted scoring of 8 disease activity variables: number of liquid or soft stools; extent of abdominal pain graded from 0 (none) to 3 (severe); general well-being rating assessed from 0 (generally well) to 4 (terrible); presence of complications; taking diphenoxylate/atropine, loperamide or opiates for diarrhea; presence of an abdominal mass (0 as none, 2 as questionable, 5 as definite); HCT: 47 in men and 42 in women and percentage deviation from standard weight, lower bound -10. Total CDAI score was calculated as the sum of variable scores*weighting factor and ranged from 0 (no disease) to 600 (severe disease), where higher scores indicated more severe disease.
Week 52 of study
Percentage of Participants With Endoscopic Response by SES-CD at Week 52: SS3 Responder Cohort
Tijdsspanne: Week 52 of study
Endoscopic response: SES-CD score <=4 and at least 2-point reduction from baseline with no subscore >1 or >=50% decrease from parent study (SS1) baseline in SES-CD. SES-CD consisted of composite score based on size of ulcers, ulcerated surface, affected surface and presence of narrowing assessed in 5 segments: ileum; right; transverse; left colon; rectum. Size of ulcers score: 0=none, 1=aphthous ulcers,2=large ulcers,3=very large ulcers. Ulcerated surface score: 0= none, 1= <10%, 2= 10% - 30%, 3= >30%. Affected surface score: 0= unaffected segment, 1= <50%,2= 50%-75%,3= >75%. Presence of narrowing score: 0=none,1=single, can be passed, 2=multiple, can be passed,3=cannot be passed. Total SES CD=sum of each domain score for all 5 bowel segments and ranged from 0 (no disease) to 60 (severe disease), higher score= more severe disease.
Week 52 of study
Percentage of Participants With Endoscopic Response by SES-CD at Week 52: SS3 Non-Responder Cohort
Tijdsspanne: Week 52 of study
Endoscopic response: SES-CD score <=4 and at least 2-point reduction from baseline with no subscore >1 or >=50% decrease from parent study (SS1) baseline in SES-CD. SES-CD consisted of composite score based on size of ulcers, ulcerated surface, affected surface and presence of narrowing assessed in 5 segments: ileum; right, transverse; left colon; rectum. Size of ulcers score: 0=none, 1=aphthous ulcers,2=large ulcers,3=very large ulcers. Ulcerated surface score: 0= none, 1= <10%, 2= 10% - 30%, 3= >30%. Affected surface score: 0= unaffected segment, 1= <50%,2= 50%-75%,3= >75%. Presence of narrowing score: 0=none,1=single, can be passed, 2=multiple, can be passed,3=cannot be passed. Total SES CD=sum of each domain score for all 5 bowel segments and ranged from 0 (no disease) to 60 (severe disease), higher score= more severe disease.
Week 52 of study

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Percentage of Participants With Clinical Remission by CDAI at Week 14: SSA
Tijdsspanne: Week 14 of SSA
Clinical remission was considered as CDAI score <150. CDAI was a composite index consisting of a weighted scoring of 8 disease activity variables: number of liquid or soft stools; extent of abdominal pain graded from 0 (none) to 3 (severe); general well-being rating assessed from 0 (generally well) to 4 (terrible); presence of complications; taking diphenoxylate/atropine, loperamide or opiates for diarrhea; presence of an abdominal mass (0 as none, 2 as questionable, 5 as definite); HCT: 47 in men and 42 in women and percentage deviation from standard weight, lower bound -10. Total CDAI score was calculated as the sum of variable scores*weighting factor and ranged from 0 (no disease) to 600 (severe disease), where higher scores indicated more severe disease.
Week 14 of SSA
Change From Baseline in SES-CD Score at Week 14: SSA
Tijdsspanne: Baseline (last measurement taken prior to the first dose of study treatment) and Week 14 of SSA
SES-CD consisted of a composite score based on 4 components: size of ulcers, ulcerated surface, affected surface and presence of narrowing assessed in 5 bowel segments: ileum; right; transverse; left colon and rectum. Size of ulcers score: 0= none, 1= aphthous ulcers, 2= large ulcers and 3= very large ulcers. Ulcerated surface score: 0= none, 1= <10%, 2= 10% - 30% and 3= >30%. Affected surface score: 0= unaffected segment, 1= <50%, 2= 50% - 75%, and 3= >75%. Presence of narrowing score: 0= none, 1= single, can be passed, 2= multiple, can be passed, 3= cannot be passed. Total SES-CD= sum of each component score for all 5 bowel segments and ranged from 0 (no disease) to 60 (severe disease), higher score indicated more severe disease.
Baseline (last measurement taken prior to the first dose of study treatment) and Week 14 of SSA
Change From Baseline in CDAI Score at Week 14: SSA
Tijdsspanne: Baseline (last measurement taken prior to the first dose of study treatment) and Week 14 of SSA
CDAI was a composite index consisting of a weighted scoring of 8 disease activity variables: number of liquid or soft stools; extent of abdominal pain graded from 0 (none) to 3 (severe); general well-being rating assessed from 0 (generally well) to 4 (terrible); presence of complications; taking diphenoxylate/atropine, loperamide or opiates for diarrhea; presence of an abdominal mass (0 as none, 2 as questionable, 5 as definite); HCT: 47 in men and 42 in women and percentage deviation from standard weight, lower bound -10. Total CDAI score was calculated as the sum of variable scores*weighting factor and ranged from 0 (no disease) to 600 (severe disease), where higher scores indicated more severe disease.
Baseline (last measurement taken prior to the first dose of study treatment) and Week 14 of SSA
Plasma Concentration of Etrasimod at 4 Hours Post-dose: SSA
Tijdsspanne: 4 hours post-dose on Day 1
The plasma concentration of etrasimod at 4 hours post-dose has been reported in this outcome measure.
4 hours post-dose on Day 1
Steady State Trough Concentration (Ctrough,ss) of Etrasimod From Week 2 to Week 14: SSA
Tijdsspanne: From Week 2 to Week 14
The average steady-state Ctrough for Week 2 through 14 was calculated based on individual Ctrough data from Week 2, Week 6 and Week 14.
From Week 2 to Week 14
Change From Baseline in Absolute Lymphocyte Count (ALC) at Week 14 in Induction Period: SSA
Tijdsspanne: Baseline (last measurement taken prior to the first dose of study treatment) and Week 14 of SSA
Baseline (last measurement taken prior to the first dose of study treatment) and Week 14 of SSA
Percent Change From Baseline in ALC at Week 14 in Induction Period: SSA
Tijdsspanne: Baseline (last measurement taken prior to the first dose of study treatment) and Week 14 of SSA
Baseline (last measurement taken prior to the first dose of study treatment) and Week 14 of SSA
Change From Baseline in ALC at Week 66 in Extension Period: SSA
Tijdsspanne: Baseline (last measurement taken prior to the first dose of study treatment) and Week 66 of SSA
Baseline (last measurement taken prior to the first dose of study treatment) and Week 66 of SSA
Percent Change From Baseline in ALC at Week 66 in Extension Period: SSA
Tijdsspanne: Baseline (last measurement taken prior to the first dose of study treatment) and Week 66 of SSA
Baseline (last measurement taken prior to the first dose of study treatment) and Week 66 of SSA
Change From Baseline in Fecal Calprotectin (FCP) Concentration at Week 14 in Induction Period: SSA
Tijdsspanne: Baseline (last measurement taken prior to the first dose of study treatment) and Week 14 of SSA
Baseline (last measurement taken prior to the first dose of study treatment) and Week 14 of SSA
Percent Change From Baseline in FCP Concentration at Week 14 in Induction Period: SSA
Tijdsspanne: Baseline (last measurement taken prior to the first dose of study treatment) and Week 14 of SSA
Baseline (last measurement taken prior to the first dose of study treatment) and Week 14 of SSA
Change From Baseline in FCP Concentration at Week 66 in Extension Period: SSA
Tijdsspanne: Baseline (last measurement taken prior to the first dose of study treatment) and Week 66 of SSA
Baseline (last measurement taken prior to the first dose of study treatment) and Week 66 of SSA
Percent Change From Baseline in FCP Concentration at Week 66 in Extension Period: SSA
Tijdsspanne: Baseline (last measurement taken prior to the first dose of study treatment) and Week 66 of SSA
Baseline (last measurement taken prior to the first dose of study treatment) and Week 66 of SSA
Change From Baseline in C-Reactive Protein (CRP) at Week 14 in Induction Period: SSA
Tijdsspanne: Baseline (last measurement taken prior to the first dose of study treatment) and Week 14 of SSA
Baseline (last measurement taken prior to the first dose of study treatment) and Week 14 of SSA
Percent Change From Baseline in CRP at Week 14 in Induction Period: SSA
Tijdsspanne: Baseline (last measurement taken prior to the first dose of study treatment) and Week 14 of SSA
Baseline (last measurement taken prior to the first dose of study treatment) and Week 14 of SSA
Change From Baseline in CRP at Week 66 in Extension Period: SSA
Tijdsspanne: Baseline (last measurement taken prior to the first dose of study treatment) and Week 66 of SSA
Baseline (last measurement taken prior to the first dose of study treatment) and Week 66 of SSA
Percent Change From Baseline in CRP at Week 66 in Extension Period: SSA
Tijdsspanne: Baseline (last measurement taken prior to the first dose of study treatment) and Week 66 of SSA
Baseline (last measurement taken prior to the first dose of study treatment) and Week 66 of SSA
Percentage of Participants With Clinical Remission by CDAI at Week 14: SS1
Tijdsspanne: Week 14 of SS1
Clinical remission was considered as CDAI score <150. CDAI was a composite index consisting of a weighted scoring of 8 disease activity variables: number of liquid or soft stools; extent of abdominal pain graded from 0 (none) to 3 (severe); general well-being rating assessed from 0 (generally well) to 4 (terrible); presence of complications; taking diphenoxylate/atropine, loperamide or opiates for diarrhea; presence of an abdominal mass (0 as none, 2 as questionable, 5 as definite); HCT: 47 in men and 42 in women and percentage deviation from standard weight, lower bound -10. Total CDAI score was calculated as the sum of variable scores*weighting factor and ranged from 0 (no disease) to 600 (severe disease), where higher scores indicated more severe disease. MI method was used; percentage was calculated based on average response rate from MI datasets.
Week 14 of SS1
Percentage of Participants With Clinical Remission by Patient Reported Outcomes 2 (PRO2) at Week 14: SS1
Tijdsspanne: Week 14 of SS1
Clinical remission was defined as PRO2 score <8. The PRO2 was a patient-reported outcome measure based on abdominal pain and stool frequency components of the CDAI. The abdominal pain rating was graded from 0 (none) to 3 (severe) each day for 7 days. The stool frequency was defined as number of liquid or soft stools each day for 7 days. Total PRO2 score was calculated as the sum of averaged abdominal pain/stool frequency variable scores*weighting factor. The PRO2 score had a minimum score of 0 and had no upper bound, with a higher score indicating more frequent stools and more severe abdominal pain. MI method was used; percentage was calculated based on average response rate from MI datasets.
Week 14 of SS1
Percentage of Participants With Clinical Remission by CDAI at Week 52 Among Participants With Clinical Remission by CDAI at SS3 Baseline: SS3 Responder Cohort
Tijdsspanne: Week 52 of study
Clinical remission was CDAI score <150. CDAI was a composite index consisting of weighted scoring of 8 disease activity variables: number of liquid or soft stools; extent of abdominal pain graded from 0 (none) to 3 (severe); general well-being rating assessed from 0 (generally well) to 4 (terrible); presence of complications; taking diphenoxylate/atropine, loperamide or opiates for diarrhea; presence of abdominal mass (0 as none, 2 as questionable, 5 as definite); HCT: 47 in men and 42 in women and percentage deviation from standard weight, lower bound -10. Total CDAI score: sum of variable scores*weighting factor and ranged from 0 (no disease) to 600 (severe disease), where higher scores= more severe disease. SS3 Baseline was last non-missing measurement taken prior to date of FMD of SS3.
Week 52 of study
Percentage of Participants With Clinical Remission by CDAI at Week 52 Among Participants With Clinical Remission by CDAI at SS3 Baseline: SS3 Non-Responder Cohort
Tijdsspanne: Week 52 of study
Clinical remission was CDAI score <150. CDAI was a composite index consisting of weighted scoring of 8 disease activity variables: number of liquid or soft stools; extent of abdominal pain graded from 0 (none) to 3 (severe); general well-being rating assessed from 0 (generally well) to 4 (terrible); presence of complications; taking diphenoxylate/atropine, loperamide or opiates for diarrhea; presence of abdominal mass (0 as none, 2 as questionable, 5 as definite); HCT: 47 in men and 42 in women and percentage deviation from standard weight, lower bound -10. Total CDAI score: sum of variable scores*weighting factor and ranged from 0 (no disease) to 600 (severe disease), where higher scores= more severe disease. SS3 Baseline was last non-missing measurement taken prior to date of FMD of SS3.
Week 52 of study
Percentage of Participants With Endoscopic Response at Week 52 Among Participants With Endoscopic Response at SS3 Baseline: SS3 Responder Cohort
Tijdsspanne: Week 52 of study
Endoscopic response: SES-CD score <=4 and at least 2-point reduction from baseline with no subscore >1 or >=50% decrease from parent study (SS1) baseline in SES-CD. SES-CD= composite score based on 4 components: size of ulcers, ulcerated surface, affected surface, presence of narrowing in 5 segments: ileum; right; transverse; left colon; rectum. Size of ulcers score: 0=none,1= aphthous ulcers, 2= large ulcers, 3= very large ulcers. Ulcerated surface score: 0= none,1= <10%, 2= 10%-30%, 3= >30%. Affected surface score: 0= unaffected segment, 1= <50%, 2= 50%-75%,3= >75%. Presence of narrowing score: 0= none,1= single, can be passed, 2= multiple can be passed, 3= can't be passed. Total SES CD=sum of component scores for 5 bowel segments and ranged from 0 (no disease) - 60 (severe disease), higher score indicated more severe disease. SS3 Baseline was last non-missing measurement taken prior to FMD date.
Week 52 of study
Percentage of Participants With Endoscopic Response at Week 52 Among Participants With Endoscopic Response at SS3 Baseline: SS3 Non-Responder Cohort
Tijdsspanne: Week 52 of study
Endoscopic response: SES-CD score <=4 and at least 2-point reduction from baseline with no subscore >1 or >=50% decrease from parent study (SS1) baseline in SES-CD. SES-CD= composite score based on 4 components: size of ulcers, ulcerated surface, affected surface, presence of narrowing in 5 segments: ileum; right; transverse; left colon; rectum. Size of ulcers score: 0=none,1= aphthous ulcers, 2= large ulcers, 3= very large ulcers. Ulcerated surface score: 0= none,1= <10%, 2= 10%-30%, 3= >30%. Affected surface score: 0= unaffected segment, 1= <50%, 2= 50%-75%,3= >75%. Presence of narrowing score: 0= none,1= single, can be passed, 2= multiple can be passed, 3= can't be passed. Total SES CD=sum of component scores for 5 bowel segments and ranged from 0 (no disease) - 60 (severe disease), higher score indicated more severe disease. SS3 Baseline was last non-missing measurement taken prior to FMD date.
Week 52 of study
Percentage of Participants With Corticosteroid-Free Clinical Remission by CDAI at Week 52 Among Participants Receiving Corticosteroids at SS3 Baseline: SS3 Responder Cohort
Tijdsspanne: Week 52 of study
Corticosteroid-free remission: CDAI score <150 without receiving corticosteroids for >=8 weeks prior to Week 52 (for participants receiving corticosteroids at baseline). CDAI: composite index consisting of weighted scoring of 8 disease activity variables: number of liquid stools; extent of abdominal pain from 0 (none)-3 (severe); general well-being from 0 (generally well)-4 (terrible); presence of complications; taking diphenoxylate/atropine, loperamide or opiates for diarrhea; presence of abdominal mass (0=none, 2=questionable, 5=definite); HCT 47 in men and 42 in women; percentage deviation from standard weight, lower bound -10. Total CDAI score=sum of variable scores*weighting factor and was from 0 (no disease)-600 (severe disease), higher score indicated more severe disease. SS3 Baseline was last non-missing measurement taken prior to date of FMD of SS3.
Week 52 of study
Percentage of Participants With Corticosteroid-Free Clinical Remission by CDAI at Week 52 Among Participants Receiving Corticosteroids at SS3 Baseline: SS3 Non-Responder Cohort
Tijdsspanne: Week 52 of study
Corticosteroid-free remission: CDAI score <150 without receiving corticosteroids for >=8 weeks prior to Week 52 (for participants receiving corticosteroids at baseline). CDAI: composite index consisting of weighted scoring of 8 disease activity variables: number of liquid stools; extent of abdominal pain from 0 (none)-3 (severe); general well-being from 0 (generally well)-4 (terrible); presence of complications; taking diphenoxylate/atropine, loperamide or opiates for diarrhea; presence of abdominal mass (0=none, 2=questionable, 5=definite); HCT 47 in men and 42 in women; percentage deviation from standard weight, lower bound -10. Total CDAI score=sum of variable scores*weighting factor and was from 0 (no disease)-600 (severe disease), higher score indicated more severe disease. SS3 Baseline was last non-missing measurement taken prior to date of FMD of SS3.
Week 52 of study
Percentage of Participants With Endoscopic Remission at Week 52: SS3 Responder Cohort
Tijdsspanne: Week 52 of study
Endoscopic remission: SES-CD score <=4 and at least 2-point reduction from baseline with no sub-score >1. SES-CD consisted of a composite score based on 4 components: size of ulcers, ulcerated surface, affected surface and presence of narrowing assessed in 5 segments: ileum; right; transverse; left colon and rectum. Size of ulcers score: 0=none, 1=aphthous ulcers, 2=large ulcers and 3=very large ulcers. Ulcerated surface score: 0= none, 1= <10%, 2= 10% - 30% and 3= >30%. Affected surface score: 0= unaffected segment, 1= <50%, 2= 50% - 75%, and 3= >75%. Presence of narrowing score: 0=none, 1= single, can be passed, 2=multiple, can be passed, 3= cannot be passed. Total SES CD=sum of each component score for all 5 bowel segments and ranged from 0 (no disease)-60 (severe disease), higher score indicated more severe disease.
Week 52 of study
Percentage of Participants With Endoscopic Remission at Week 52: SS3 Non-Responder Cohort
Tijdsspanne: Week 52 of study
Endoscopic remission: SES-CD score <=4 and at least 2-point reduction from baseline with no sub-score >1. SES-CD consisted of a composite score based on 4 components: size of ulcers, ulcerated surface, affected surface and presence of narrowing assessed in 5 segments: ileum; right; transverse; left colon and rectum. Size of ulcers score: 0=none, 1=aphthous ulcers, 2=large ulcers and 3=very large ulcers. Ulcerated surface score: 0= none, 1= <10%, 2= 10% - 30% and 3= >30%. Affected surface score: 0= unaffected segment, 1= <50%, 2= 50% - 75%, and 3= >75%. Presence of narrowing score: 0=none, 1= single, can be passed, 2=multiple, can be passed, 3= cannot be passed. Total SES CD=sum of each component score for all 5 bowel segments and ranged from 0 (no disease)-60 (severe disease), higher score indicated more severe disease.
Week 52 of study
Percentage of Participants With Clinical Remission by PRO2 at Week 52: SS3 Responder Cohort
Tijdsspanne: Week 52 of study
Clinical remission was defined as PRO2 score <8. The PRO2 was a patient-reported outcome measure based on abdominal pain and stool frequency components of the CDAI. The abdominal pain rating was graded from 0 (none) to 3 (severe) each day for 7 days. The stool frequency was defined as number of liquid or soft stools each day for 7 days. Total PRO2 score was calculated as the sum of averaged abdominal pain/stool frequency variable scores*weighting factor. The PRO2 score had a minimum score of 0 and had no upper bound, with a higher score indicating more frequent stools and more severe abdominal pain.
Week 52 of study
Percentage of Participants With Clinical Remission by PRO2 at Week 52: SS3 Non-Responder Cohort
Tijdsspanne: Week 52 of study
Clinical remission was defined as PRO2 score <8. The PRO2 was a patient-reported outcome measure based on abdominal pain and stool frequency components of the CDAI. The abdominal pain rating was graded from 0 (none) to 3 (severe) each day for 7 days. The stool frequency was defined as number of liquid or soft stools each day for 7 days. Total PRO2 score was calculated as the sum of averaged abdominal pain/stool frequency variable scores*weighting factor. The PRO2 score had a minimum score of 0 and had no upper bound, with a higher score indicating more frequent stools and more severe abdominal pain.
Week 52 of study
Percentage of Participants With Clinical Response or Endoscopic Response at Week 52: SS3 Responder Cohort
Tijdsspanne: Week 52 of study
Clinical response: clinical remission CDAI or >=100-point decrease from baseline in CDAI score where, clinical remission CDAI=CDAI <150. CDAI: composite index consisting of weighted scoring of 8 disease activity variables. Total CDAI: sum of variable scores*weighting factor and ranged from 0 (no disease) - 600 (severe disease), higher scores indicated more severe disease. Endoscopic response: SES-CD score <=4 and at least 2-point reduction from baseline with no subscore >1 or >=50% decrease from baseline in SES-CD. SES-CD comprised of 4 components assessed for 5 bowel segments. Each component score ranged from 0-3, higher scores indicated more severe condition. Total SES CD: sum of each component score of 5 bowel segments and ranged from 0 (no D) - 60 (severe disease), higher score indicated more severe disease. Percentage of participants with clinical response or endoscopic response at Week 52 is reported.
Week 52 of study
Percentage of Participants With Clinical Response or Endoscopic Response at Week 52: SS3 Non-Responder Cohort
Tijdsspanne: Week 52 of study
Clinical response: clinical remission CDAI or >=100-point decrease from baseline in CDAI score where, clinical remission CDAI=CDAI <150. CDAI: composite index consisting of weighted scoring of 8 disease activity variables. Total CDAI: sum of variable scores*weighting factor and ranged from 0 (no disease) - 600 (severe disease), higher scores indicated more severe disease. Endoscopic response: SES-CD score <=4 and at least 2-point reduction from baseline with no subscore >1 or >=50% decrease from baseline in SES-CD. SES-CD comprised of 4 components assessed for 5 bowel segments. Each component score ranged from 0-3, higher scores indicated more severe condition. Total SES CD: sum of each component score of 5 bowel segments and ranged from 0 (no D) - 60 (severe disease), higher score indicated more severe disease. Percentage of participants with clinical response or endoscopic response at Week 52 is reported.
Week 52 of study
Change From Baseline in CDAI Score at Weeks 20, 28, 36, 44 and 52: SS3 Responder Cohort
Tijdsspanne: Baseline, study Weeks 20, 28, 36, 44, 52
CDAI was a composite index consisting of a weighted scoring of 8 disease activity variables: number of liquid or soft stools; extent of abdominal pain graded from 0 (none) to 3 (severe); general well-being rating assessed from 0 (generally well) to 4 (terrible); presence of complications; taking diphenoxylate/atropine, loperamide or opiates for diarrhea; presence of an abdominal mass (0 as none, 2 as questionable, 5 as definite); HCT 47 in men and 42 in women and percentage deviation from standard weight, lower bound -10. Total CDAI score was calculated as the sum of variable scores*weighting factor and ranged from 0 (no disease) to 600 (severe disease), where higher scores indicated more severe disease. SS3 Baseline was last non-missing measurement taken prior to date of FMD of SS3.
Baseline, study Weeks 20, 28, 36, 44, 52
Change From Baseline in CDAI Score at Weeks 20, 28, 36, 44 and 52: SS3 Non-Responder Cohort
Tijdsspanne: Baseline, study Weeks 20, 28, 36, 44, 52
CDAI was a composite index consisting of a weighted scoring of 8 disease activity variables: number of liquid or soft stools; extent of abdominal pain graded from 0 (none) to 3 (severe); general well-being rating assessed from 0 (generally well) to 4 (terrible); presence of complications; taking diphenoxylate/atropine, loperamide or opiates for diarrhea; presence of an abdominal mass (0 as none, 2 as questionable, 5 as definite); HCT 47 in men and 42 in women and percentage deviation from standard weight, lower bound -10. Total CDAI score was calculated as the sum of variable scores*weighting factor and ranged from 0 (no disease) to 600 (severe disease), where higher scores indicated more severe disease. SS3 Baseline was last non-missing measurement taken prior to date of FMD of SS3.
Baseline, study Weeks 20, 28, 36, 44, 52
Percentage of Participants With Clinical Response by CDAI at Week 52 Among Participants With Clinical Response by CDAI at SS3 Baseline: SS3 Responder Cohort
Tijdsspanne: Week 52 of study
Clinical Response was clinical remission by CDAI or >=100-point decrease from baseline in CDAI score where, clinical remission CDAI= CDAI <150. CDAI: composite index consisting of weighted scoring of 8 disease activity variables: number of liquid or soft stools; extent of abdominal pain graded from 0 (none)-3 (severe); general well-being rating assessed from 0 (generally well) - 4 (terrible); presence of complications; taking diphenoxylate/atropine, loperamide/opiates for diarrhea; presence of an abdominal mass (0=none, 2=questionable, 5=definite); HCT 47 in men and 42 in women and percentage deviation from standard weight, lower bound -10. Total CDAI score= sum of variable scores*weighting factor and ranged from 0 (no disease) - 600 (severe disease), where higher scores indicated more severe disease. SS3 Baseline= last non-missing measurement taken prior to date of FMD of SS3.
Week 52 of study
Percentage of Participants With Clinical Response by CDAI at Week 52 Among Participants With Clinical Response by CDAI at SS3 Baseline: SS3 Non-Responder Cohort
Tijdsspanne: Week 52 of study
Clinical Response was clinical remission by CDAI or >=100-point decrease from baseline in CDAI score where, clinical remission CDAI= CDAI <150. CDAI: composite index consisting of weighted scoring of 8 disease activity variables: number of liquid or soft stools; extent of abdominal pain graded from 0 (none)-3 (severe); general well-being rating assessed from 0 (generally well) - 4 (terrible); presence of complications; taking diphenoxylate/atropine, loperamide/opiates for diarrhea; presence of an abdominal mass (0=none, 2=questionable, 5=definite); HCT 47 in men and 42 in women and percentage deviation from standard weight, lower bound -10. Total CDAI score= sum of variable scores*weighting factor and ranged from 0 (no disease) - 600 (severe disease), where higher scores indicated more severe disease. SS3 Baseline= last non-missing measurement taken prior to date of FMD of SS3.
Week 52 of study
Change From Baseline in Crohn's Disease Patient-Reported Outcomes (CD-PRO) Module Scores at Weeks 28 and 52: SS3 Responder Cohort
Tijdsspanne: Baseline, study Weeks 28 and 52
The CD-PRO was a validated instrument designed to assess the signs, symptoms, and impact of CD through 6 modules: Systemic Symptoms, Coping Strategies, Daily Life Impact, Emotional Impact, Bowel Signs and Symptoms and Functional Symptoms. Each module ranged from 0 to 16, where higher scores indicated more severe disease. SS3 Baseline was defined as last non-missing measurement taken prior to date of FMD of SS3.
Baseline, study Weeks 28 and 52
Change From Baseline in Crohn's Disease Patient-Reported Outcomes (CD-PRO) Module Scores at Weeks 28 and 52: SS3 Non-Responder Cohort
Tijdsspanne: Baseline, study Weeks 28 and 52
The CD-PRO was a validated instrument designed to assess the signs, symptoms, and impact of CD through 6 modules: Systemic Symptoms, Coping Strategies, Daily Life Impact, Emotional Impact, Bowel Signs and Symptoms and Functional Symptoms. Each module ranged from 0 to 16, where higher scores indicated more severe disease. SS3 Baseline was defined as last non-missing measurement taken prior to date of FMD of SS3.
Baseline, study Weeks 28 and 52
Change From Baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) at Weeks 28 and 52: SS3 Responder Cohort
Tijdsspanne: Baseline, study Weeks 28 and 52
The IBDQ was a validated 32 item questionnaire used to assess health related quality of life in participants with IBD. Response to each of the questions ranged from 1 to 7 where higher scores indicated better quality of life. The total IBDQ scores were calculated as sum of individual item scores and ranged from 32 (very poor health-related quality of life) to 224 (perfect health-related quality of life) where higher scores indicated better quality of life. SS3 Baseline was defined as last non-missing measurement taken prior to date of FMD of SS3.
Baseline, study Weeks 28 and 52
Change From Baseline in IBDQ at Weeks 28 and 52: SS3 Non-Responder Cohort
Tijdsspanne: Baseline, study Weeks 28 and 52
The IBDQ was a validated 32 item questionnaire used to assess health related quality of life in participants with IBD. Response to each of the questions ranged from 1 to 7 where higher scores indicated better quality of life. The total IBDQ scores were calculated as sum of individual item scores and ranged from 32 (very poor health-related quality of life) to 224 (perfect health-related quality of life) where higher scores indicated better quality of life. SS3 Baseline was defined as last non-missing measurement taken prior to date of FMD of SS3.
Baseline, study Weeks 28 and 52
Change From Baseline in Medical Outcomes Study 36-Item Short Form Health Survey (SF-36) at Weeks 28 and 52: SS3 Responder Cohort
Tijdsspanne: Baseline, study Weeks 28 and 52
The SF-36 was a health-related survey that assessed participant's health status and consisted of 36 questions measuring 8 health domains: physical functioning, bodily pain, role limitations due to physical problems, role limitations due to emotional problems, general health perceptions, mental health, social function and vitality. The 8 domains are combined to form 2 component scores mental (MCS) and physical (PCS). MCS consisted of social functioning, vitality, mental health, and role-emotional scales. PCS consisted of physical functioning, bodily pain, role-physical, and general health scales. Each domain was scored by summing the individual items and transforming the total SF-36 scores into a 0 to 100 scale with higher scores indicating better health status. SS3 Baseline= last non-missing measurement taken prior to date of FMD of SS3.
Baseline, study Weeks 28 and 52
Change From Baseline in SF-36 at Weeks 28 and 52: SS3 Non-Responder Cohort
Tijdsspanne: Baseline, study Weeks 28 and 52
The SF-36 was a health-related survey that assessed participant's health status and consisted of 36 questions measuring 8 health domains: physical functioning, bodily pain, role limitations due to physical problems, role limitations due to emotional problems, general health perceptions, mental health, social function and vitality. The 8 domains are combined to form 2 component scores MCS and PCS. MCS consisted of social functioning, vitality, mental health, and role-emotional scales. PCS consisted of physical functioning, bodily pain, role-physical, and general health scales. Each domain was scored by summing the individual items and transforming the total SF-36 scores into a 0 to 100 scale with higher scores indicating better health status. SS3 Baseline= last non-missing measurement taken prior to date of FMD of SS3.
Baseline, study Weeks 28 and 52
Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) at Weeks 28 and 52: SS3 Responder Cohort
Tijdsspanne: Baseline, study Weeks 28 and 52
The FACIT-F was a participant completed questionnaire consisting of 13 items that assess fatigue. Participants responded to each item on a 5-point scale based on their experience of fatigue during the past 7 days (0 = not at all; 1 = a little bit; 2 =somewhat; 3 = quite a bit; 4 = very much). Instrument scoring yielded a total FACIT-F score range from 0 to 52 (negatively worded items were reversed during analysis), with higher scores representing better participant status (less fatigue). SS3 Baseline= last non-missing measurement taken prior to date of FMD of SS3.
Baseline, study Weeks 28 and 52
Change From Baseline in FACIT-F at Weeks 28 and 52: SS3 Non-Responder Cohort
Tijdsspanne: Baseline, study Weeks 28 and 52
The FACIT-F was a participant completed questionnaire consisting of 13 items that assess fatigue. Participants responded to each item on a 5-point scale based on their experience of fatigue during the past 7 days (0 = not at all; 1 = a little bit; 2 =somewhat; 3 = quite a bit; 4 = very much). Instrument scoring yielded a total FACIT-F score range from 0 to 52 (negatively worded items were reversed during analysis), with higher scores representing better participant status (less fatigue). SS3 Baseline= last non-missing measurement taken prior to date of FMD of SS3.
Baseline, study Weeks 28 and 52
Percentage of Participants With Clinical Remission by PRO2 at Week 52 Among Participants With Clinical Remission by PRO2 at SS3 Baseline: SS3 Responder Cohort
Tijdsspanne: Week 52 of study
Clinical remission was defined as PRO2 score <8. The PRO2 was a patient-reported outcome measure based on abdominal pain and stool frequency components of the CDAI. The abdominal pain rating was graded from 0 (none) to 3 (severe) each day for 7 days. The stool frequency was defined as number of liquid or soft stools each day for 7 days. Total PRO2 score was calculated as the sum of averaged abdominal pain/stool frequency variable scores*weighting factor. The PRO2 score had a minimum score of 0 and had no upper bound, with a higher score indicating more frequent stools and more severe abdominal pain. SS3 Baseline was defined as last non-missing measurement taken prior to date of FMD of SS3.
Week 52 of study
Percentage of Participants With Clinical Remission by PRO2 at Week 52 Among Participants With Clinical Remission by PRO2 at Study Entry: SS3 Non-Responder Cohort
Tijdsspanne: Week 52 of study
Clinical remission was defined as PRO2 score <8. The PRO2 was a patient-reported outcome measure based on abdominal pain and stool frequency components of the CDAI. The abdominal pain rating was graded from 0 (none) to 3 (severe) each day for 7 days. The stool frequency was defined as number of liquid or soft stools each day for 7 days. Total PRO2 score was calculated as the sum of averaged abdominal pain/stool frequency variable scores*weighting factor. The PRO2 score had a minimum score of 0 and had no upper bound, with a higher score indicating more frequent stools and more severe abdominal pain. SS3 Baseline was defined as last non-missing measurement taken prior to date of FMD of SS3.
Week 52 of study
Change From Baseline in PRO2 Scores at Weeks 20, 28, 36, 44 and 52: SS3 Responder Cohort
Tijdsspanne: Baseline, study Weeks 20, 28, 36, 44 and 52
The PRO2 was a patient-reported outcome measure based on abdominal pain and stool frequency components of the CDAI. The abdominal pain rating was graded from 0 (none) to 3 (severe) each day for 7 days. The stool frequency was defined as number of liquid or soft stools each day for 7 days. Total PRO2 score was calculated as the sum of averaged abdominal pain/stool frequency variable scores*weighting factor. The PRO2 score had a minimum score of 0 and had no upper bound, with a higher score indicating more frequent stools and more severe abdominal pain. SS3 Baseline was defined as last non-missing measurement taken prior to date of FMD of SS3.
Baseline, study Weeks 20, 28, 36, 44 and 52
Change From Baseline in PRO2 Scores at Weeks 20, 28, 36, 44 and 52: SS3 Non-Responder Cohort
Tijdsspanne: Baseline, study Weeks 20, 28, 36, 44 and 52
The PRO2 was a patient-reported outcome measure based on abdominal pain and stool frequency components of the CDAI. The abdominal pain rating was graded from 0 (none) to 3 (severe) each day for 7 days. The stool frequency was defined as number of liquid or soft stools each day for 7 days. Total PRO2 score was calculated as the sum of averaged abdominal pain/stool frequency variable scores*weighting factor. The PRO2 score had a minimum score of 0 and had no upper bound, with a higher score indicating more frequent stools and more severe abdominal pain. SS3 Baseline was defined as last non-missing measurement taken prior to date of FMD of SS3.
Baseline, study Weeks 20, 28, 36, 44 and 52
Time to Remission by PRO2 and FCP Concentrations: SS3 Responder Cohort
Tijdsspanne: From first maintenance dose in SS3 until date of clinical remission and FCP normalization or censoring date (maximum up to 42 weeks)
Time to remission by PRO2 and FCP concentrations was defined as time to onset of clinical remission by PRO2 and FCP normalization. Clinical remission by PRO2 was defined as PRO2 score <8. Normalization of FCP was defined as FCP <=150 milligrams per kilogram. The PRO2 was a patient-reported outcome measure based on abdominal pain and stool frequency components of the CDAI. The abdominal pain rating was graded from 0 (none) to 3 (severe) each day for 7 days. The stool frequency was defined as number of liquid or soft stools each day for 7 days. Total PRO2 score was calculated as the sum of averaged abdominal pain/stool frequency variable scores*weighting factor. The PRO2 score had a minimum score of 0 and had no upper bound, with a higher score indicating more frequent stools and more severe abdominal pain. Participants who did not achieve remission or discontinued from study were censored at 7 days after last dose of study drug.
From first maintenance dose in SS3 until date of clinical remission and FCP normalization or censoring date (maximum up to 42 weeks)
Time to Remission by PRO2 and FCP Concentrations: SS3 Non-Responder Cohort
Tijdsspanne: From first maintenance dose in SS3 until date of clinical remission and FCP normalization or censoring date (maximum up to 42 weeks)
Time to remission by PRO2 and FCP concentrations was defined as time to onset of clinical remission by PRO2 and FCP normalization. Clinical remission by PRO2 was defined as PRO2 score <8. Normalization of FCP was defined as FCP <=150 milligrams per kilogram. The PRO2 was a patient-reported outcome measure based on abdominal pain and stool frequency components of the CDAI. The abdominal pain rating was graded from 0 (none) to 3 (severe) each day for 7 days. The stool frequency was defined as number of liquid or soft stools each day for 7 days. Total PRO2 score was calculated as the sum of averaged abdominal pain/stool frequency variable scores*weighting factor. The PRO2 score had a minimum score of 0 and had no upper bound, with a higher score indicating more frequent stools and more severe abdominal pain. Participants who did not achieve remission or discontinued from study were censored at 7 days after last dose of study drug.
From first maintenance dose in SS3 until date of clinical remission and FCP normalization or censoring date (maximum up to 42 weeks)
Time to Response by PRO2 and FCP Concentrations: SS3 Responder Cohort
Tijdsspanne: From first maintenance dose in SS3 until date of clinical response and FCP normalization or censoring date (maximum up to 42 weeks)
Time to response by PRO2 and FCP concentrations: time to onset of PRO2 response and FCP normalization. Clinical response by PRO2: clinical remission by PRO2 or >= 8-point decrease from baseline in PRO2 score. Clinical remission by PRO2: PRO2 score <8. Normalization of FCP: FCP <=150 milligrams per kilogram. The PRO2 was a patient-reported outcome measure based on abdominal pain and stool frequency components of the CDAI. The abdominal pain rating was graded from 0 (none) to 3 (severe) each day for 7 days. The stool frequency was defined as number of liquid or soft stools each day for 7 days. Total PRO2 score was calculated as the sum of averaged abdominal pain/stool frequency variable scores*weighting factor. The PRO2 score had a minimum score of 0 and had no upper bound, with a higher score indicating more frequent stools and more severe abdominal pain. Participants who did not achieve response or discontinued from study were censored at 7 days after last dose of study drug.
From first maintenance dose in SS3 until date of clinical response and FCP normalization or censoring date (maximum up to 42 weeks)
Time to Response by PRO2 and FCP Concentrations: SS3 Non-Responder Cohort
Tijdsspanne: From first maintenance dose in SS3 until date of clinical response and FCP normalization or censoring date (maximum up to 42 weeks)
Time to response by PRO2 and FCP concentrations: time to onset of PRO2 response and FCP normalization. Clinical response by PRO2: clinical remission by PRO2 or >= 8-point decrease from baseline in PRO2 score. Clinical remission by PRO2: PRO2 score <8. Normalization of FCP: FCP <=150 milligrams per kilogram. The PRO2 was a patient-reported outcome measure based on abdominal pain and stool frequency components of the CDAI. The abdominal pain rating was graded from 0 (none) to 3 (severe) each day for 7 days. The stool frequency was defined as number of liquid or soft stools each day for 7 days. Total PRO2 score was calculated as the sum of averaged abdominal pain/stool frequency variable scores*weighting factor. The PRO2 score had a minimum score of 0 and had no upper bound, with a higher score indicating more frequent stools and more severe abdominal pain. Participants who did not achieve response or discontinued from study were censored at 7 days after last dose of study drug.
From first maintenance dose in SS3 until date of clinical response and FCP normalization or censoring date (maximum up to 42 weeks)
Change From Baseline in SES-CD Score at Week 52: SS3 Responder Cohort
Tijdsspanne: Baseline and Week 52 of study
SES-CD was an endoscopic grading system which consisted of composite score based on 4 components: size of ulcers, ulcerated surface, affected surface and presence of narrowing assessed in 5 segments: ileum; right; transverse; left colon and rectum. Size of ulcers score: 0= none, 1= aphthous ulcers, 2=large ulcers and 3=very large ulcers. Ulcerated surface score: 0=none, 1= <10%, 2= 10% - 30% and 3= >30%. Affected surface score: 0=unaffected segment, 1= <50%, 2= 50% - 75%, and 3= >75%. Presence of narrowing score: 0=none, 1=single, can be passed, 2=multiple can be passed, 3=cannot be passed. Total SES CD= sum of each component score for all 5 bowel segments and ranged from 0 (no disease)-60 (severe disease), higher score indicated more severe disease. SS3 Baseline= last non-missing measurement taken prior to date of FMD of SS3.
Baseline and Week 52 of study
Change From Baseline in SES-CD Score at Week 52: SS3 Non-Responder Cohort
Tijdsspanne: Baseline and Week 52 of study
SES-CD was an endoscopic grading system which consisted of composite score based on 4 components: size of ulcers, ulcerated surface, affected surface and presence of narrowing assessed in 5 segments: ileum; right; transverse; left colon and rectum. Size of ulcers score: 0= none, 1= aphthous ulcers, 2=large ulcers and 3=very large ulcers. Ulcerated surface score: 0=none, 1= <10%, 2= 10% - 30% and 3= >30%. Affected surface score: 0=unaffected segment, 1= <50%, 2= 50% - 75%, and 3= >75%. Presence of narrowing score: 0=none, 1=single, can be passed, 2=multiple can be passed, 3=cannot be passed. Total SES CD= sum of each component score for all 5 bowel segments and ranged from 0 (no disease)-60 (severe disease), higher score indicated more severe disease. SS3 Baseline= last non-missing measurement taken prior to date of FMD of SS3.
Baseline and Week 52 of study
Percentage of Participants With Endoscopic Response and Clinical Remission by PRO2 at Week 52: SS3 Responder Cohort
Tijdsspanne: Week 52 of study
Endoscopic response: SES-CD score <=4 and at least 2-point reduction from baseline with no subscore >1 or >=50% decrease from parent study (SS1) baseline in SES-CD. SES-CD had 4 components assessed for 5 bowel segments where, each component score ranged from 0 to 3, higher scores=more severe condition. Total SES CD score was determined by sum of each component score for all 5 bowel segments and ranged from 0-60, higher score=more severe disease. Clinical remission by PRO2: PRO2 score <8. PRO2 was patient-reported outcome measure based on abdominal pain and stool frequency components of CDAI. Abdominal pain graded from 0 (none)-3 (severe) each day for 7 days. Stool frequency was number of liquid or soft stools each day for 7 days. Total PRO2 score calculated as sum of averaged abdominal pain/stool frequency variable scores*weighting factor. PRO2 score had minimum score of 0 and had no upper bound, with higher score indicating more frequent stools and more severe abdominal pain.
Week 52 of study
Percentage of Participants With Endoscopic Response and Clinical Remission by PRO2 at Week 52: SS3 Non-Responder Cohort
Tijdsspanne: Week 52 of study
Endoscopic response: SES-CD score <=4 and at least 2-point reduction from baseline with no subscore >1 or >=50% decrease from parent study (SS1) baseline in SES-CD. SES-CD had 4 components assessed for 5 bowel segments where, each component score ranged from 0 to 3, higher scores=more severe condition. Total SES CD score was determined by sum of each component score for all 5 bowel segments and ranged from 0-60, higher score=more severe disease. Clinical remission by PRO2: PRO2 score <8. PRO2 was patient-reported outcome measure based on abdominal pain and stool frequency components of CDAI. Abdominal pain graded from 0 (none)-3 (severe) each day for 7 days. Stool frequency was number of liquid or soft stools each day for 7 days. Total PRO2 score calculated as sum of averaged abdominal pain/stool frequency variable scores*weighting factor. PRO2 score had minimum score of 0 and had no upper bound, with higher score indicating more frequent stools and more severe abdominal pain.
Week 52 of study
Percentage of Participants With Endoscopic Remission and Clinical Remission by PRO2 at Week 52: SS3 Responder Cohort
Tijdsspanne: Week 52 of study
Endoscopic remission: SES-CD <=4 and at least 2-point reduction from baseline with no sub-score >1. SES-CD comprised of 4 components assessed for 5 bowel segments where, each component score ranged from 0 to 3, higher scores indicated more severe condition. Total SES CD score was determined by sum of each component score for all 5 bowel segments and ranged from 0 to 60, higher score indicated more severe disease. Clinical remission by PRO2 was defined as PRO2 score <8. PRO2 was patient-reported outcome measure based on abdominal pain and stool frequency components of CDAI. The abdominal pain rating was graded from 0 (none) to 3 (severe) each day for 7 days. Stool frequency was number of liquid or soft stools each day for 7 days. Total PRO2 score was calculated as sum of averaged abdominal pain/stool frequency variable scores*weighting factor. PRO2 score had a minimum score of 0 and had no upper bound, with higher score indicating more frequent stools and more severe abdominal pain.
Week 52 of study
Percentage of Participants With Endoscopic Remission and Clinical Remission by PRO2 at Week 52: SS3 Non-Responder Cohort
Tijdsspanne: Week 52 of study
Endoscopic remission: SES-CD <=4 and at least 2-point reduction from baseline with no sub-score >1. SES-CD comprised of 4 components assessed for 5 bowel segments where, each component score ranged from 0 to 3, higher scores indicated more severe condition. Total SES CD score was determined by sum of each component score for all 5 bowel segments and ranged from 0 to 60, higher score indicated more severe disease. Clinical remission by PRO2 was defined as PRO2 score <8. PRO2 was patient-reported outcome measure based on abdominal pain and stool frequency components of CDAI. The abdominal pain rating was graded from 0 (none) to 3 (severe) each day for 7 days. Stool frequency was number of liquid or soft stools each day for 7 days. Total PRO2 score was calculated as sum of averaged abdominal pain/stool frequency variable scores*weighting factor. PRO2 score had a minimum score of 0 and had no upper bound, with higher score indicating more frequent stools and more severe abdominal pain.
Week 52 of study
Number of Participants According to Markedly Abnormal Criteria for Electrocardiogram (ECG) Parameters: SS4
Tijdsspanne: Baseline, Weeks 52, and 104 of SS4
Pre-defined markedly abnormal criteria for ECG parameters included: QT interval: >500 (milliseconds [msec]); change from SS4 baseline >30 msec and change from SS4 baseline >60 msec. QT interval corrected using Fridericia's formula (QTcF) (msec): >=450 (male) or >=470 (female) msec; change from SS4 baseline >30 msec; change from SS4 baseline >60 msec. PR interval (msec): >230 msec. Only those ECG parameters in which at least 1 participant in any of the reporting arm had markedly abnormal criteria are reported in this outcome measure. SS4 Baseline was defined as the last non-missing measurement taken up to the date of first dose in the SS4.
Baseline, Weeks 52, and 104 of SS4
Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), TEAEs by Severity and Treatment Related TEAEs: SS3
Tijdsspanne: From first dose of study treatment (Day 1) up to 4 weeks post last dose of study treatment (maximum treatment exposure: 38 weeks; maximum follow-up: 42 weeks)
AE: any untoward medical occurrence that did not necessarily have a causal relationship with treatment. SAE: an AE that met one of the following criteria: resulted in death; was life-threatening; required inpatient or prolongation of existing hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect or medically significant. AEs were graded by the National Cancer Institute Common Terminology Criteria for AE version 5 where, Grade(G) 1: mild AE; G2: moderate; G3: severe; G4: life-threatening consequences, urgent intervention indicated; G5: death related to AE. AE was considered TEAE if it started or worsened in severity on or after the first dose of study treatment. Treatment related AEs were AEs that were related to the study treatment and relatedness was judged by investigator.
From first dose of study treatment (Day 1) up to 4 weeks post last dose of study treatment (maximum treatment exposure: 38 weeks; maximum follow-up: 42 weeks)
Number of Participants With TEAEs of Special Interest: SS3
Tijdsspanne: From first dose of study treatment (Day 1) up to 4 weeks post last dose of study treatment (maximum treatment exposure: 38 weeks; maximum follow-up: 42 weeks)
The TEAEs of special interest included: cardiovascular events (bradycardia, atrioventricular [AV] conduction delay, and hypertension); macular edema; pulmonary disorders (airflow obstruction [forced expiratory volume in 1 second, and forced vital capacity], decreased gas exchange [diffusing capacity of the lung for carbon monoxide]); infections (severe infections, opportunistic infections, and herpes simplex and herpes zoster); liver injury (liver transaminases elevation, and bilirubin elevation); posterior reversible encephalopathy syndrome; and malignancies. Number of participants with any TEAEs of special interest were reported in this outcome measure.
From first dose of study treatment (Day 1) up to 4 weeks post last dose of study treatment (maximum treatment exposure: 38 weeks; maximum follow-up: 42 weeks)
Number of Participants With Clinically Meaningful Changes in Laboratory Parameters: SS3
Tijdsspanne: From first dose of study treatment (Day 1) up to 4 weeks post last dose of study treatment (maximum treatment exposure: 38 weeks; maximum follow-up: 42 weeks)
Clinically meaningful laboratory abnormalities:Hemoglobin, Hematocrit, Erythrocytes (<0.8*LLN); Ery. Volume, Hemoglobin,Mean Corpuscular HGB Concentration <0.8*LLN or >1.5*LLN;Reticulocytes, Leukocytes, Lymphocytes, Neutrophils, Neutrophils, Basophils, Eosinophils, Monocytes (>1.2*ULN), Prothrombin Time(>1.1*ULN).Clinical Chemistry: Bilirubin, Direct Bilirubin, Indirect Bilirubin (1.5*ULN), Aspartate Aminotransferase, Alanine Aminotransferase, Gamma Glutamyl Transferase, Alkaline Phosphatase (>3.0*ULN); Albumin, Urate (<0.8*LLN and >1.2*ULN; Urea Nitrogen,Creatinine Cholesterol >1.3*ULN; Cholesterol <0.8*LLN or >1.2*LLN, Triglycerides,Potassium,Calcium < 0.9x LLN & >1.1x ULN; Bicarbonate, Glucose, Creatine Kinase. Urinalysis: Glucose, Ketones, Protein, Hemoglobin, Urobilinogen, Bilirubin, Nitrite >=1; Leukocyte Erythrocytes, Leukocytes >=20; Epithelial Cells>=6, Hyaline Cast>1; Bacteria>20. Number of participants with any laboratory abnormality meeting specified criteria is included.
From first dose of study treatment (Day 1) up to 4 weeks post last dose of study treatment (maximum treatment exposure: 38 weeks; maximum follow-up: 42 weeks)
Number of Participants With TEAEs, SAEs, TEAEs by Severity and Treatment Related TEAEs: SS4
Tijdsspanne: From first dose of study treatment (Day 1) up to 4 weeks post last dose of study treatment (maximum treatment exposure: 166.3 weeks; maximum follow-up: 170.3 weeks)
AE: any untoward medical occurrence that did not necessarily have a causal relationship with treatment. SAE: an AE that met one of the following criteria: resulted in death; was life-threatening; required inpatient or prolongation of existing hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect or medically significant. AEs were graded by the National Cancer Institute Common Terminology Criteria for AE version 5 where, G1: mild AE; G2: moderate; G3: severe; G4: life-threatening consequences, urgent intervention indicated; G5: death related to AE. AE was considered TEAE if it started or worsened in severity on or after the first dose of study treatment. Treatment related AEs were AEs that were related to the study treatment and relatedness was judged by investigator.
From first dose of study treatment (Day 1) up to 4 weeks post last dose of study treatment (maximum treatment exposure: 166.3 weeks; maximum follow-up: 170.3 weeks)
Number of Participants With TEAEs of Special Interest: SS4
Tijdsspanne: From first dose of study treatment (Day 1) up to 4 weeks post last dose of study treatment (maximum treatment exposure: 166.3 weeks; maximum follow-up: 170.3 weeks)
The TEAEs of special interest included: cardiovascular events (bradycardia, AV conduction delay, and hypertension); macular edema; pulmonary disorders (airflow obstruction [forced expiratory volume in 1 second, and forced vital capacity], decreased gas exchange [diffusing capacity of the lung for carbon monoxide]); infections (severe infections, opportunistic infections, and herpes simplex and herpes zoster); liver injury (liver transaminases elevation, and bilirubin elevation); posterior reversible encephalopathy syndrome; and malignancies. Number of participants with any TEAEs of special interest were reported in this outcome measure.
From first dose of study treatment (Day 1) up to 4 weeks post last dose of study treatment (maximum treatment exposure: 166.3 weeks; maximum follow-up: 170.3 weeks)
Number of Participants With Clinically Meaningful Changes in Laboratory Parameters: SS4
Tijdsspanne: From first dose of study treatment (Day 1) up to 4 weeks post last dose of study treatment (maximum treatment exposure: 166.3 weeks; maximum follow-up: 170.3 weeks)
Clinically meaningful laboratory abnormalities:Hemoglobin, Hematocrit, Erythrocytes (<0.8*LLN); Ery. Volume, Hemoglobin,Mean Corpuscular HGB Concentration <0.8*LLN or >1.5*LLN;Reticulocytes, Leukocytes, Lymphocytes, Neutrophils, Neutrophils, Basophils, Eosinophils, Monocytes (>1.2*ULN), Prothrombin Time(>1.1*ULN).Clinical Chemistry: Bilirubin, Direct Bilirubin, Indirect Bilirubin (1.5*ULN), Aspartate Aminotransferase, Alanine Aminotransferase, Gamma Glutamyl Transferase, Alkaline Phosphatase (>3.0*ULN); Albumin, Urate (<0.8*LLN and >1.2*ULN; Urea Nitrogen,Creatinine Cholesterol >1.3*ULN; Cholesterol <0.8*LLN or >1.2*LLN, Triglycerides,Potassium,Calcium < 0.9x LLN & >1.1x ULN; Bicarbonate, Glucose, Creatine Kinase. Urinalysis: Glucose, Ketones, Protein, Hemoglobin, Urobilinogen, Bilirubin, Nitrite >=1; Leukocyte Erythrocytes, Leukocytes >=20; Epithelial Cells>=6, Hyaline Cast>1; Bacteria>20. Number of participants with any laboratory abnormality meeting specified criteria is included.
From first dose of study treatment (Day 1) up to 4 weeks post last dose of study treatment (maximum treatment exposure: 166.3 weeks; maximum follow-up: 170.3 weeks)
Number of Participants According to Markedly Abnormal Criteria for Vital Signs: SS4
Tijdsspanne: Baseline, Weeks 1, 12, 24, 36, 52, 64, 76, 88 and 104 of SS4
Pre-defined markedly abnormal criteria for vital signs included: Systolic blood pressure (millimeters of mercury [mmHg]): low: <=90 mmHg and high: >150 mmHg. Diastolic blood pressure (mmHg): low: <=50 mmHg and high: >90 mmHg. Heart rate (beats per minute [bpm]): low: <40 bpm, <50 bpm and high: >100 bpm. Only those vital signs parameters in which at least 1 participant in any of the reporting arm had markedly abnormal criteria are reported in this outcome measure. SS4 baseline=the last non-missing measurement taken up to the date of first dose in the SS4.
Baseline, Weeks 1, 12, 24, 36, 52, 64, 76, 88 and 104 of SS4
Percentage of Participants With Clinical Remission by CDAI at Weeks 12, 24, 36, 52, 64, 76, 88 and 104: SS4
Tijdsspanne: Weeks 12, 24, 36, 52, 64, 76, 88 and 104 of SS4
Clinical remission was considered as CDAI score <150. CDAI was a composite index consisting of a weighted scoring of 8 disease activity variables: number of liquid or soft stools; extent of abdominal pain graded from 0 (none) to 3 (severe); general well-being rating assessed from 0 (generally well) to 4 (terrible); presence of complications; taking diphenoxylate/atropine, loperamide or opiates for diarrhea; presence of an abdominal mass (0 as none, 2 as questionable, 5 as definite); HCT 47 in men and 42 in women and percentage deviation from standard weight, lower bound -10. Total CDAI score was calculated as the sum of variable scores*weighting factor and ranged from 0 (no disease) to 600 (severe disease), where higher scores indicated more severe disease.
Weeks 12, 24, 36, 52, 64, 76, 88 and 104 of SS4
Percentage of Participants With Clinical Response by CDAI at Weeks 12, 24, 36, 52, 64, 76, 88 and 104: SS4
Tijdsspanne: Weeks 12, 24, 36, 52, 64, 76, 88 and 104 of SS4
Clinical Response was defined as having clinical remission CDAI or >=100-point decrease from baseline in CDAI score where, clinical remission was considered as CDAI <150. CDAI was a composite index consisting of a weighted scoring of 8 disease activity variables: number of liquid or soft stools; extent of abdominal pain graded from 0 (none) to 3 (severe); general well-being rating assessed from 0 (generally well) to 4 (terrible); presence of complications; taking diphenoxylate/atropine, loperamide or opiates for diarrhea; presence of an abdominal mass (0 as none, 2 as questionable, 5 as definite); HCT 47 in men and 42 in women and percentage deviation from standard weight, lower bound -10. Total CDAI score was calculated as the sum of variable scores*weighting factor and ranged from 0 (no disease) to 600 (severe disease), where higher scores indicated more severe disease.
Weeks 12, 24, 36, 52, 64, 76, 88 and 104 of SS4
Percentage of Participants With Clinical Remission by PRO2 at Weeks 12, 24, 36, 52, 64, 76, 88 and 104: SS4
Tijdsspanne: Weeks 12, 24, 36, 52, 64, 76, 88 and 104 of SS4
Clinical remission was defined as PRO2 score <8. The PRO2 was a patient-reported outcome measure based on abdominal pain and stool frequency components of the CDAI. The abdominal pain rating was graded from 0 (none) to 3 (severe) each day for 7 days. The stool frequency was defined as number of liquid or soft stools each day for 7 days. Total PRO2 score was calculated as the sum of averaged abdominal pain/stool frequency variable scores*weighting factor. The PRO2 score had a minimum score of 0 and had no upper bound, with a higher score indicating more frequent stools and more severe abdominal pain.
Weeks 12, 24, 36, 52, 64, 76, 88 and 104 of SS4

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Sponsor

Onderzoekers

  • Studie directeur: Pfizer CT.gov Call Center, Pfizer

Publicaties en nuttige links

De persoon die verantwoordelijk is voor het invoeren van informatie over het onderzoek stelt deze publicaties vrijwillig ter beschikking. Dit kan gaan over alles wat met het onderzoek te maken heeft.

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

6 januari 2020

Primaire voltooiing (Werkelijk)

23 april 2025

Studie voltooiing (Werkelijk)

9 juni 2025

Studieregistratiedata

Eerst ingediend

20 november 2019

Eerst ingediend dat voldeed aan de QC-criteria

20 november 2019

Eerst geplaatst (Werkelijk)

21 november 2019

Updates van studierecords

Laatste update geplaatst (Werkelijk)

1 juli 2026

Laatste update ingediend die voldeed aan QC-criteria

5 juni 2026

Laatst geverifieerd

1 juni 2026

Meer informatie

Termen gerelateerd aan deze studie

Andere studie-ID-nummers

  • APD334-202
  • C5041006 (Andere identificatie: Alias Study Number)
  • 2024-513569-38-00 (Register-ID: CTIS (EU))

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

JA

Beschrijving IPD-plan

Pfizer zal toegang verlenen tot gegevens van individuele geanonimiseerde deelnemers en gerelateerde onderzoeksdocumenten (bijv. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) op verzoek van gekwalificeerde onderzoekers en onder voorbehoud van bepaalde criteria, voorwaarden en uitzonderingen. Meer details over Pfizer's criteria voor het delen van gegevens en het proces voor het aanvragen van toegang zijn te vinden op: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Ja

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

product vervaardigd in en geëxporteerd uit de V.S.

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren